Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030096951 A1
Publication typeApplication
Application numberUS 09/374,046
Publication dateMay 22, 2003
Filing dateAug 13, 1999
Priority dateAug 14, 1998
Also published asUS7344861, US20040038276, US20060177904, US20080139452
Publication number09374046, 374046, US 2003/0096951 A1, US 2003/096951 A1, US 20030096951 A1, US 20030096951A1, US 2003096951 A1, US 2003096951A1, US-A1-20030096951, US-A1-2003096951, US2003/0096951A1, US2003/096951A1, US20030096951 A1, US20030096951A1, US2003096951 A1, US2003096951A1
InventorsKenneth Jacobs, John McCoy, Edward LaVallie, Lisa Collins-Racie, David Merberg, Michael Agostino, Robert Steininger, Vikki Spaulding, Gordon Wong, Hilary Clark, Kim Fechtel, Cheryl Evans, Maurice Treacy
Original AssigneeKenneth Jacobs, Mccoy John M., Lavallie Edward R., Collins-Racie Lisa A., David Merberg, Agostino Michael J., Robert Steininger, Vikki Spaulding, Wong Gordon G., Clark Hilary F., Kim Fechtel, Cheryl Evans, Maurice Treacy
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Secreted proteins and polynucleotides encoding them
US 20030096951 A1
Abstract
Novel polynucleotides and the proteins encoded thereby are disclosed.
Images(3)
Previous page
Next page
Claims(13)
What is claimed is:
1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:41;
(b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348;
(c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348;
(d) the nucleotide sequence of the full-length protein coding sequence of clone dd50418 deposited under accession number ATCC 98850;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
(f) the nucleotide sequence of a mature protein coding sequence of clone dd50418 deposited under accession number ATCC 98850;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 65 degrees C., or 4×SSC at 42 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 50 degrees C., or 6×SSC at 40 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:41.
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
(a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2; and
(b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. An isolated polynucleotide encoding the protein of claim 6.
8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone dd50418 deposited under accession number ATCC 98850.
9. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:42;
(b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and
(c) the amino acid sequence encoded by the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins.
10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:42.
11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:51;
(b) the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783;
(c) the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783;
(d) the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938;
(e) the nucleotide sequence of the full-length protein coding sequence of clone qs143 deposited under accession number ATCC 98850;
(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
(g) the nucleotide sequence of a mature protein coding sequence of clone qs143 deposited under accession number ATCC 98850;
(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:52;
(j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;
(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 65 degrees C., or 4×SSC at 42 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and
(l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4×SSC at 50 degrees C., or 6×SSC at 40 degrees C. with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:51.
13. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:52;
(b) the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135;
(c) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and
(d) the amino acid sequence encoded by the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
the protein being substantially free from other mammalian proteins.
Description
  • [0001]
    This application is a continuation-in-part of the following applications:
  • [0002]
    (1) provisional application Ser. No. 60/096,622 (GI 6075), filed Aug. 14, 1998;
  • [0003]
    (2) provisional application Ser. No. 60/096,815 (GI 6076), filed Aug. 17, 1998;
  • [0004]
    (3) provisional application Ser. No. 60/099,229 (GI 6077), filed Sep. 4, 1998;
  • [0005]
    (4) provisional application Ser. No. 60/105,368 (GI 6078), filed Oct. 23, 1998;
  • [0006]
    (5) provisional application Ser. No. 60/115,234 (GI 6079), filed Jan. 8, 1999;
  • [0007]
    (6) provisional application Ser. No. 60/119,931 (GI 6080), filed Feb. 12, 1999;
  • [0008]
    (7) provisional application Ser. No. 60/120,575 (GI 6081), filed Feb. 18, 1999;
  • [0009]
    (8) provisional application Ser. No. 60/132,020 (GI 6082), filed Apr. 30, 1999;
  • [0010]
    (9) provisional application Ser. No. ______ (GI 6083), filed Aug. 11, 1999;
  • [0011]
    all of which are incorporated by reference herein.
  • FIELD OF THE INVENTION
  • [0012]
    The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
  • BACKGROUND OF THE INVENTION
  • [0013]
    Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques done novel polynucleotides “directly” in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent “indirect” cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.
  • SUMMARY OF THE INVENTION
  • [0014]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0015]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
  • [0016]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821;
  • [0017]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821;
  • [0018]
    (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625;
  • [0019]
    (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone co6212 deposited under accession number ATCC 98825;
  • [0020]
    (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone co6212 deposited under accession number ATCC 98825;
  • [0021]
    (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone co6212 deposited under accession number ATCC 98825;
  • [0022]
    (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone co6212 deposited under accession number ATCC 98825;
  • [0023]
    (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
  • [0024]
    (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
  • [0025]
    (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
  • [0026]
    (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above;
  • [0027]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
  • [0028]
    (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:1.
  • [0029]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821; the nucleotide sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821; the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625; the nucleotide sequence of the full-length protein coding sequence of clone co6212 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone co6212 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone co6212 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.
  • [0030]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.
  • [0031]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0032]
    (a) a process comprising the steps of:
  • [0033]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0034]
    (aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:1; and
  • [0035]
    (ab) the nucleotide sequence of the cDNA insert of clone co6212 deposited under accession number ATCC 98825;
  • [0036]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0037]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0038]
    (b) a process comprising the steps of:
  • [0039]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0040]
    (ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:1; and
  • [0041]
    (bb) the nucleotide sequence of the cDNA insert of clone co6212 deposited under accession number ATCC 98825;
  • [0042]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0043]
    (iii) amplifying human DNA sequences; and
  • [0044]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0045]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:1, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625.
  • [0046]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0047]
    (a) the amino acid sequence of SEQ ID NO:2;
  • [0048]
    (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and
  • [0049]
    (c) the amino acid sequence encoded by the cDNA insert of clone co6212 deposited under accession number ATCC 98825;
  • [0050]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.
  • [0051]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0052]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
  • [0053]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013;
  • [0054]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013;
  • [0055]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone lo3118 deposited under accession number ATCC 98825;
  • [0056]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone lo3118 deposited under accession number ATCC 98825;
  • [0057]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone lo3118 deposited under accession number ATCC 98825;
  • [0058]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone lo3118 deposited under accession number ATCC 98825;
  • [0059]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
  • [0060]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;
  • [0061]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0062]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0063]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0064]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.
  • [0065]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013; the nucleotide sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013; the nucleotide sequence of the full-length protein coding sequence of clone lo3118 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone lo3118 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone lo3118 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.
  • [0066]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.
  • [0067]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0068]
    (a) a process comprising the steps of:
  • [0069]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0070]
    (aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:3; and
  • [0071]
    (ab) the nucleotide sequence of the cDNA insert of clone lo3118 deposited under accession number ATCC 98825;
  • [0072]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0073]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0074]
    (b) a process comprising the steps of:
  • [0075]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0076]
    (ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:3; and
  • [0077]
    (bb) the nucleotide sequence of the cDNA insert of clone lo3118 deposited under accession number ATCC 98825;
  • [0078]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0079]
    (iii) amplifying human DNA sequences; and
  • [0080]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0081]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:3, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013.
  • [0082]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0083]
    (a) the amino acid sequence of SEQ ID NO:4;
  • [0084]
    (b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and
  • [0085]
    (c) the amino acid sequence encoded by the cDNA insert of clone lo3118 deposited under accession number ATCC 98825;
  • [0086]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino add sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.
  • [0087]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0088]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
  • [0089]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825;
  • [0090]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ns1971 deposited under accession number ATCC 98825;
  • [0091]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ns1971 deposited under accession number ATCC 98825;
  • [0092]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ns1971 deposited under accession number ATCC 98825;
  • [0093]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ns1971 deposited under accession number ATCC 98825;
  • [0094]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
  • [0095]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;
  • [0096]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0097]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0098]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0099]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:5.
  • [0100]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825; the nucleotide sequence of the full-length protein coding sequence of clone ns1971 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone ns1971 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ns1971 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thiy) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.
  • [0101]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.
  • [0102]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0103]
    (a) a process comprising the steps of:
  • [0104]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0105]
    (aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:5; and
  • [0106]
    (ab) the nucleotide sequence of the cDNA insert of clone ns1971 deposited under accession number ATCC 98825;
  • [0107]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0108]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0109]
    (b) a process comprising the steps of:
  • [0110]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0111]
    (ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:5; and
  • [0112]
    (bb) the nucleotide sequence of the cDNA insert of clone ns1971 deposited under accession number ATCC 98825;
  • [0113]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0114]
    (iii) amplifying human DNA sequences; and
  • [0115]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0116]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:5, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825.
  • [0117]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0118]
    (a) the amino acid sequence of SEQ ID NO:6;
  • [0119]
    (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and
  • [0120]
    (c) the amino acid sequence encoded by the cDNA insert of clone ns1971 deposited under accession number ATCC 98825;
  • [0121]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.
  • [0122]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0123]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
  • [0124]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829;
  • [0125]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829;
  • [0126]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pj1935 deposited under accession number ATCC 98825;
  • [0127]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pj1935 deposited under accession number ATCC 98825;
  • [0128]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pj1935 deposited under accession number ATCC 98825;
  • [0129]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pj1935 deposited under accession number ATCC 98825;
  • [0130]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
  • [0131]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
  • [0132]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0133]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0134]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0135]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7.
  • [0136]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829; the nucleotide sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829; the nucleotide sequence of the full-length protein coding sequence of clone pj1935 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pj1935 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pj1935 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.
  • [0137]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.
  • [0138]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0139]
    (a) a process comprising the steps of:
  • [0140]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0141]
    (aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:7; and
  • [0142]
    (ab) the nucleotide sequence of the cDNA insert of clone pj1935 deposited under accession number ATCC 98825;
  • [0143]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0144]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0145]
    (b) a process comprising the steps of:
  • [0146]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0147]
    (ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:7; and
  • [0148]
    (bb) the nucleotide sequence of the cDNA insert of clone pj1935 deposited under accession number ATCC 98825;
  • [0149]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0150]
    (iii) amplifying human DNA sequences; and
  • [0151]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0152]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:7, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829.
  • [0153]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0154]
    (a) the amino acid sequence of SEQ ID NO:8;
  • [0155]
    (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
  • [0156]
    (c) the amino acid sequence encoded by the cDNA insert of clone pj1935 deposited under accession number ATCC 98825;
  • [0157]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.
  • [0158]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0159]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
  • [0160]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292;
  • [0161]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pj3172 deposited under accession number ATCC 98825;
  • [0162]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pj3172 deposited under accession number ATCC 98825;
  • [0163]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pj3172 deposited under accession number ATCC 98825;
  • [0164]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pj3172 deposited under accession number ATCC 98825;
  • [0165]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
  • [0166]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
  • [0167]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0168]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0169]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0170]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:9.
  • [0171]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292; the nucleotide sequence of the full-length protein coding sequence of clone pj3172 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pj3172 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pj3172 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.
  • [0172]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.
  • [0173]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0174]
    (a) a process comprising the steps of:
  • [0175]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0176]
    (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:9; and
  • [0177]
    (ab) the nucleotide sequence of the cDNA insert of done pj3172 deposited under accession number ATCC 98825;
  • [0178]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0179]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0180]
    (b) a process comprising the steps of:
  • [0181]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0182]
    (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:9; and
  • [0183]
    (bb) the nucleotide sequence of the cDNA insert of clone pj3172 deposited under accession number ATCC 98825;
  • [0184]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0185]
    (iii) amplifying human DNA sequences; and
  • [0186]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0187]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:9, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292.
  • [0188]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0189]
    (a) the amino acid sequence of SEQ ID NO:10;
  • [0190]
    (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
  • [0191]
    (c) the amino acid sequence encoded by the cDNA insert of clone pj3172 deposited under accession number ATCC 98825;
  • [0192]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.
  • [0193]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0194]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
  • [0195]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517;
  • [0196]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517;
  • [0197]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt3321 deposited under accession number ATCC 98825;
  • [0198]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pt3321 deposited under accession number ATCC 98825;
  • [0199]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pt3321 deposited under accession number ATCC 98825;
  • [0200]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pt3321 deposited under accession number ATCC 98825;
  • [0201]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
  • [0202]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
  • [0203]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0204]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0205]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0206]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:11.
  • [0207]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517; the nucleotide sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517; the nucleotide sequence of the full-length protein coding sequence of done pt3321 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pt3321 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pt3321 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.
  • [0208]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.
  • [0209]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0210]
    (a) a process comprising the steps of:
  • [0211]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0212]
    (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:11; and
  • [0213]
    (ab) the nucleotide sequence of the cDNA insert of clone pt3321 deposited under accession number ATCC 98825;
  • [0214]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0215]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0216]
    (b) a process comprising the steps of:
  • [0217]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0218]
    (ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:11; and
  • [0219]
    (bb) the nucleotide sequence of the cDNA insert of clone pt3321 deposited under accession number ATCC 98825;
  • [0220]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0221]
    (iii) amplifying human DNA sequences; and
  • [0222]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0223]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:11, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517.
  • [0224]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0225]
    (a) the amino acid sequence of SEQ ID NO:12;
  • [0226]
    (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and
  • [0227]
    (c) the amino acid sequence encoded by the cDNA insert of clone pt3321 deposited under accession number ATCC 98825;
  • [0228]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.
  • [0229]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0230]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
  • [0231]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257;
  • [0232]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qc29715 deposited under accession number ATCC 98825;
  • [0233]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qc29715 deposited under accession number ATCC 98825;
  • [0234]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qc29715 deposited under accession number ATCC 98825;
  • [0235]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qc29715 deposited under accession number ATCC 98825;
  • [0236]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
  • [0237]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;
  • [0238]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0239]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0240]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0241]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:13.
  • [0242]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257; the nucleotide sequence of the full-length protein coding sequence of clone qc29715 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qc29715 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qc29715 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:14.
  • [0243]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.
  • [0244]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0245]
    (a) a process comprising the steps of:
  • [0246]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0247]
    (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:13; and
  • [0248]
    (ab) the nucleotide sequence of the cDNA insert of clone qc29715 deposited under accession number ATCC 98825;
  • [0249]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0250]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0251]
    (b) a process comprising the steps of:
  • [0252]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0253]
    (ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:13; and
  • [0254]
    (bb) the nucleotide sequence of the cDNA insert of clone qc29715 deposited under accession number ATCC 98825;
  • [0255]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0256]
    (iii) amplifying human DNA sequences; and
  • [0257]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0258]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:13, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257.
  • [0259]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0260]
    (a) the amino acid sequence of SEQ ID NO:14;
  • [0261]
    (b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and
  • [0262]
    (c) the amino acid sequence encoded by the cDNA insert of clone qc29715 deposited under accession number ATCC 98825;
  • [0263]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:14.
  • [0264]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0265]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
  • [0266]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432;
  • [0267]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qg59612 deposited under accession number ATCC 98825;
  • [0268]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qg59612 deposited under accession number ATCC 98825;
  • [0269]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qg59612 deposited under accession number ATCC 98825;
  • [0270]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qg59612 deposited under accession number ATCC 98825;
  • [0271]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
  • [0272]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
  • [0273]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0274]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0275]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0276]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:15.
  • [0277]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432; the nucleotide sequence of the full-length protein coding sequence of clone qg59612 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qg59612 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qg59612 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.
  • [0278]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.
  • [0279]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0280]
    (a) a process comprising the steps of:
  • [0281]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0282]
    (aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:15; and
  • [0283]
    (ab) the nucleotide sequence of the cDNA insert of clone qg59612 deposited under accession number ATCC 98825;
  • [0284]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0285]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0286]
    (b) a process comprising the steps of:
  • [0287]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0288]
    (ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:15; and
  • [0289]
    (bb) the nucleotide sequence of the cDNA insert of clone qg59612 deposited under accession number ATCC 98825;
  • [0290]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0291]
    (iii) amplifying human DNA sequences; and
  • [0292]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0293]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:15, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432.
  • [0294]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0295]
    (a) the amino acid sequence of SEQ ID NO:16;
  • [0296]
    (b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and
  • [0297]
    (c) the amino acid sequence encoded by the cDNA insert of clone qg59612 deposited under accession number ATCC 98825;
  • [0298]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.
  • [0299]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0300]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
  • [0301]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105;
  • [0302]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105;
  • [0303]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rb6493 deposited under accession number ATCC 98825;
  • [0304]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rb6493 deposited under accession number ATCC 98825;
  • [0305]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rb6493 deposited under accession number ATCC 98825;
  • [0306]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rb6493 deposited under accession number ATCC 98825;
  • [0307]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
  • [0308]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;
  • [0309]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0310]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0311]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0312]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:17.
  • [0313]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105; the nucleotide sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105; the nucleotide sequence of the full-length protein coding sequence of clone rb6493 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone rb6493 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done rb6493 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.
  • [0314]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.
  • [0315]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0316]
    (a) a process comprising the steps of:
  • [0317]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0318]
    (aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:17; and
  • [0319]
    (ab) the nucleotide sequence of the cDNA insert of clone rb6493 deposited under accession number ATCC 98825;
  • [0320]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0321]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0322]
    (b) a process comprising the steps of:
  • [0323]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0324]
    (ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:17; and
  • [0325]
    (bb) the nucleotide sequence of the cDNA insert of clone rb6493 deposited under accession number ATCC 98825;
  • [0326]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0327]
    (iii) amplifying human DNA sequences; and
  • [0328]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0329]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:17, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105.
  • [0330]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0331]
    (a) the amino acid sequence of SEQ ID NO:18;
  • [0332]
    (b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and
  • [0333]
    (c) the amino acid sequence encoded by the cDNA insert of clone rb6493 deposited under accession number ATCC 98825;
  • [0334]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.
  • [0335]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0336]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
  • [0337]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467;
  • [0338]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ca10619x deposited under accession number ATCC 98835;
  • [0339]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ca10619x deposited under accession number ATCC 98835;
  • [0340]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ca10619x deposited under accession number ATCC 98835;
  • [0341]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ca10619×deposited under accession number ATCC 98835;
  • [0342]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
  • [0343]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;
  • [0344]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0345]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0346]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0347]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:19.
  • [0348]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467; the nucleotide sequence of the full-length protein coding sequence of clone ca10619x deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone ca10619x deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ca10619x deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.
  • [0349]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.
  • [0350]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0351]
    (a) a process comprising the steps of:
  • [0352]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0353]
    (aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:19; and
  • [0354]
    (ab) the nucleotide sequence of the cDNA insert of clone ca10619x deposited under accession number ATCC 98835;
  • [0355]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0356]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0357]
    (b) a process comprising the steps of:
  • [0358]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0359]
    (ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:19; and
  • [0360]
    (bb) the nucleotide sequence of the cDNA insert of clone ca10619x deposited under accession number ATCC 98835;
  • [0361]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0362]
    (iii) amplifying human DNA sequences; and
  • [0363]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0364]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:19, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467.
  • [0365]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0366]
    (a) the amino acid sequence of SEQ ID NO:20;
  • [0367]
    (b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and
  • [0368]
    (c) the amino acid sequence encoded by the cDNA insert of clone ca10619x deposited under accession number ATCC 98835;
  • [0369]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.
  • [0370]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0371]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21;
  • [0372]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802;
  • [0373]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802;
  • [0374]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of done ci522 deposited under accession number ATCC 98835;
  • [0375]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ci522 deposited under accession number ATCC 98835;
  • [0376]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ci522 deposited under accession number ATCC 98835;
  • [0377]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ci522 deposited under accession number ATCC 98835;
  • [0378]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:22;
  • [0379]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;
  • [0380]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0381]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0382]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0383]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.
  • [0384]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802; the nucleotide sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802; the nucleotide sequence of the full-length protein coding sequence of clone ci522 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone ci522 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ci522 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.
  • [0385]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:21.
  • [0386]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0387]
    (a) a process comprising the steps of:
  • [0388]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0389]
    (aa) SEQ ID NO:21, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:21; and
  • [0390]
    (ab) the nucleotide sequence of the cDNA insert of done ci522 deposited under accession number ATCC 98835;
  • [0391]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0392]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0393]
    (b) a process comprising the steps of:
  • [0394]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0395]
    (ba) SEQ ID NO:21, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:21; and
  • [0396]
    (bb) the nucleotide sequence of the cDNA insert of clone ci522 deposited under accession number ATCC 98835;
  • [0397]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0398]
    (iii) amplifying human DNA sequences; and
  • [0399]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0400]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:21, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:21. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802.
  • [0401]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0402]
    (a) the amino acid sequence of SEQ ID NO:22;
  • [0403]
    (b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and
  • [0404]
    (c) the amino acid sequence encoded by the cDNA insert of clone ci522 deposited under accession number ATCC 98835;
  • [0405]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:22. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.
  • [0406]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0407]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
  • [0408]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714;
  • [0409]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714;
  • [0410]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone md12416 deposited under accession number ATCC 98835;
  • [0411]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone md12416 deposited under accession number ATCC 98835;
  • [0412]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone md12416 deposited under accession number ATCC 98835;
  • [0413]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone md12416 deposited under accession number ATCC 98835;
  • [0414]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
  • [0415]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;
  • [0416]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0417]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0418]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0419]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:23.
  • [0420]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714; the nucleotide sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714; the nucleotide sequence of the full-length protein coding sequence of clone md12416 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone md12416 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone md12416 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.
  • [0421]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:23.
  • [0422]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0423]
    (a) a process comprising the steps of:
  • [0424]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0425]
    (aa) SEQ ID NO:23, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:23; and
  • [0426]
    (ab) the nucleotide sequence of the cDNA insert of clone md12416 deposited under accession number ATCC 98835;
  • [0427]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0428]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0429]
    (b) a process comprising the steps of:
  • [0430]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0431]
    (ba) SEQ ID NO:23, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:23; and
  • [0432]
    (bb) the nucleotide sequence of the cDNA insert of clone md12416 deposited under accession number ATCC 98835;
  • [0433]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0434]
    (iii) amplifying human DNA sequences; and
  • [0435]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0436]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:23, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714.
  • [0437]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0438]
    (a) the amino acid sequence of SEQ ID NO:24;
  • [0439]
    (b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and
  • [0440]
    (c) the amino acid sequence encoded by the cDNA insert of clone md12416 deposited under accession number ATCC 98835;
  • [0441]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:24. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.
  • [0442]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0443]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25;
  • [0444]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726;
  • [0445]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726;
  • [0446]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pk3667 deposited under accession number ATCC 98835;
  • [0447]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pk3667 deposited under accession number ATCC 98835;
  • [0448]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pk3667 deposited under accession number ATCC 98835;
  • [0449]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pk3667 deposited under accession number ATCC 98835;
  • [0450]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:26;
  • [0451]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;
  • [0452]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0453]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0454]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0455]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:25.
  • [0456]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726; the nucleotide sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726; the nucleotide sequence of the full-length protein coding sequence of clone pk3667 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pk3667 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pk3667 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino add 267 to amino acid 276 of SEQ ID NO:26.
  • [0457]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:25.
  • [0458]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0459]
    (a) a process comprising the steps of:
  • [0460]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0461]
    (aa) SEQ ID NO:25, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:25; and
  • [0462]
    (ab) the nucleotide sequence of the cDNA insert of clone pk3667 deposited under accession number ATCC 98835;
  • [0463]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0464]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0465]
    (b) a process comprising the steps of:
  • [0466]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0467]
    (ba) SEQ ID NO:25, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:25; and
  • [0468]
    (bb) the nucleotide sequence of the cDNA insert of clone pk3667 deposited under accession number ATCC 98835;
  • [0469]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0470]
    (iii) amplifying human DNA sequences; and
  • [0471]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0472]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:25, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726.
  • [0473]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0474]
    (a) the amino acid sequence of SEQ ID NO:26;
  • [0475]
    (b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and
  • [0476]
    (c) the amino acid sequence encoded by the cDNA insert of clone pk3667 deposited under accession number ATCC 98835;
  • [0477]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 267 to amino acid 276 of SEQ ID NO:26.
  • [0478]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0479]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;
  • [0480]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788;
  • [0481]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788;
  • [0482]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pl7415 deposited under accession number ATCC 98835;
  • [0483]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pl7415 deposited under accession number ATCC 98835;
  • [0484]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pl7415 deposited under accession number ATCC 98835;
  • [0485]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pl7415 deposited under accession number ATCC 98835;
  • [0486]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
  • [0487]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;
  • [0488]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0489]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0490]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0491]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.
  • [0492]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788; the nucleotide sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788; the nucleotide sequence of the full-length protein coding sequence of clone pl7415 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pl7415 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pl7415 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.
  • [0493]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.
  • [0494]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0495]
    (a) a process comprising the steps of:
  • [0496]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0497]
    (aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:27; and
  • [0498]
    (ab) the nucleotide sequence of the cDNA insert of clone pl7415 deposited under accession number ATCC 98835;
  • [0499]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0500]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0501]
    (b) a process comprising the steps of:
  • [0502]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0503]
    (ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:27; and
  • [0504]
    (bb) the nucleotide sequence of the cDNA insert of clone pl7415 deposited under accession number ATCC 98835;
  • [0505]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0506]
    (iii) amplifying human DNA sequences; and
  • [0507]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0508]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:27, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788.
  • [0509]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0510]
    (a) the amino acid sequence of SEQ ID NO:28;
  • [0511]
    (b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and
  • [0512]
    (c) the amino acid sequence encoded by the cDNA insert of clone pl7415 deposited under accession number ATCC 98835;
  • [0513]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.
  • [0514]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0515]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;
  • [0516]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338;
  • [0517]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pp31419 deposited under accession number ATCC 98835;
  • [0518]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pp31419 deposited under accession number ATCC 98835;
  • [0519]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pp31419 deposited under accession number ATCC 98835;
  • [0520]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pp31419 deposited under accession number ATCC 98835;
  • [0521]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;
  • [0522]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;
  • [0523]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0524]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0525]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0526]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:29.
  • [0527]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338; the nucleotide sequence of the full-length protein coding sequence of clone pp31419 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pp31419 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pp31419 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.
  • [0528]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29.
  • [0529]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0530]
    (a) a process comprising the steps of:
  • [0531]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0532]
    (aa) SEQ ID NO:29, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:29; and
  • [0533]
    (ab) the nucleotide sequence of the cDNA insert of clone pp31419 deposited under accession number ATCC 98835;
  • [0534]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0535]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0536]
    (b) a process comprising the steps of:
  • [0537]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0538]
    (ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:29; and
  • [0539]
    (bb) the nucleotide sequence of the cDNA insert of done pp31419 deposited under accession number ATCC 98835;
  • [0540]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0541]
    (iii) amplifying human DNA sequences; and
  • [0542]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0543]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:29, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338.
  • [0544]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0545]
    (a) the amino acid sequence of SEQ ID NO:30;
  • [0546]
    (b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and
  • [0547]
    (c) the amino acid sequence encoded by the cDNA insert of clone pp31419 deposited under accession number ATCC 98835;
  • [0548]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.
  • [0549]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0550]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31;
  • [0551]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102;
  • [0552]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pv351 deposited under accession number ATCC 98835;
  • [0553]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pv351 deposited under accession number ATCC 98835;
  • [0554]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pv351 deposited under accession number ATCC 98835;
  • [0555]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pv351 deposited under accession number ATCC 98835;
  • [0556]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32;
  • [0557]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;
  • [0558]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0559]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0560]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0561]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:31.
  • [0562]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102; the nucleotide sequence of the full-length protein coding sequence of clone pv351 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pv351 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv351 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.
  • [0563]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:31.
  • [0564]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0565]
    (a) a process comprising the steps of:
  • [0566]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0567]
    (aa) SEQ ID NO:31, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:31; and
  • [0568]
    (ab) the nucleotide sequence of the cDNA insert of clone pv351 deposited under accession number ATCC 98835;
  • [0569]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0570]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0571]
    (b) a process comprising the steps of:
  • [0572]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0573]
    (ba) SEQ ID NO:31, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:31; and
  • [0574]
    (bb) the nucleotide sequence of the cDNA insert of clone pv351 deposited under accession number ATCC 98835;
  • [0575]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0576]
    (iii) amplifying human DNA sequences; and
  • [0577]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0578]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:31, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102.
  • [0579]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0580]
    (a) the amino acid sequence of SEQ ID NO:32;
  • [0581]
    (b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and
  • [0582]
    (c) the amino acid sequence encoded by the cDNA insert of clone pv351 deposited under accession number ATCC 98835;
  • [0583]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:32. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.
  • [0584]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0585]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33;
  • [0586]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733;
  • [0587]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pw3376 deposited under accession number ATCC 98835;
  • [0588]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pw3376 deposited under accession number ATCC 98835;
  • [0589]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pw3376 deposited under accession number ATCC 98835;
  • [0590]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pw3376 deposited under accession number ATCC 98835;
  • [0591]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:34;
  • [0592]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;
  • [0593]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0594]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0595]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0596]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:33.
  • [0597]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733; the nucleotide sequence of the full-length protein coding sequence of clone pw3376 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pw3376 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pw3376 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.
  • [0598]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:33.
  • [0599]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0600]
    (a) a process comprising the steps of:
  • [0601]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0602]
    (aa) SEQ ID NO:33, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:33; and
  • [0603]
    (ab) the nucleotide sequence of the cDNA insert of clone pw3376 deposited under accession number ATCC 98835;
  • [0604]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0605]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0606]
    (b) a process comprising the steps of:
  • [0607]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0608]
    (ba) SEQ ID NO:33, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:33; and
  • [0609]
    (bb) the nucleotide sequence of the cDNA insert of clone pw3376 deposited under accession number ATCC 98835;
  • [0610]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0611]
    (iii) amplifying human DNA sequences; and
  • [0612]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0613]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:33 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:33, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733.
  • [0614]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0615]
    (a) the amino acid sequence of SEQ ID NO:34;
  • [0616]
    (b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and
  • [0617]
    (c) the amino acid sequence encoded by the cDNA insert of clone pw3376 deposited under accession number ATCC 98835;
  • [0618]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:34. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.
  • [0619]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0620]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;
  • [0621]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938;
  • [0622]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd6101 deposited under accession number ATCC 98835;
  • [0623]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd6101 deposited under accession number ATCC 98835;
  • [0624]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd6101 deposited under accession number ATCC 98835;
  • [0625]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd6101 deposited under accession number ATCC 98835;
  • [0626]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
  • [0627]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;
  • [0628]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0629]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0630]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0631]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:35.
  • [0632]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938; the nucleotide sequence of the full-length protein coding sequence of clone rd6101 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone rd6101 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd6101 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.
  • [0633]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:35.
  • [0634]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0635]
    (a) a process comprising the steps of:
  • [0636]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0637]
    (aa) SEQ ID NO:35, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:35; and
  • [0638]
    (ab) the nucleotide sequence of the cDNA insert of clone rd6101 deposited under accession number ATCC 98835;
  • [0639]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0640]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0641]
    (b) a process comprising the steps of:
  • [0642]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0643]
    (ba) SEQ ID NO:35, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:35; and
  • [0644]
    (bb) the nucleotide sequence of the cDNA insert of clone rd6101 deposited under accession number ATCC 98835;
  • [0645]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0646]
    (iii) amplifying human DNA sequences; and
  • [0647]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0648]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:35 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:35, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938.
  • [0649]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0650]
    (a) the amino acid sequence of SEQ ID NO:36;
  • [0651]
    (b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and
  • [0652]
    (c) the amino acid sequence encoded by the cDNA insert of clone rd6101 deposited under accession number ATCC 98835;
  • [0653]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:36. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.
  • [0654]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0655]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37;
  • [0656]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494;
  • [0657]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494;
  • [0658]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd8106 deposited under accession number ATCC 98835;
  • [0659]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd8106 deposited under accession number ATCC 98835;
  • [0660]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd8106 deposited under accession number ATCC 98835;
  • [0661]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd8106 deposited under accession number ATCC 98835;
  • [0662]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:38;
  • [0663]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;
  • [0664]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0665]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0666]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0667]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:37.
  • [0668]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494; the nucleotide sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494; the nucleotide sequence of the full-length protein coding sequence of clone rd8106 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone rd8106 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd8106 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.
  • [0669]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:37.
  • [0670]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0671]
    (a) a process comprising the steps of:
  • [0672]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0673]
    (aa) SEQ ID NO:37, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:37; and
  • [0674]
    (ab) the nucleotide sequence of the cDNA insert of clone rd8106 deposited under accession number ATCC 98835;
  • [0675]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0676]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0677]
    (b) a process comprising the steps of:
  • [0678]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0679]
    (ba) SEQ ID NO:37, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:37; and
  • [0680]
    (bb) the nucleotide sequence of the cDNA insert of clone rd8106 deposited under accession number ATCC 98835;
  • [0681]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0682]
    (iii) amplifying human DNA sequences; and
  • [0683]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0684]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:37, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494.
  • [0685]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0686]
    (a) the amino acid sequence of SEQ ID NO:38;
  • [0687]
    (b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and
  • [0688]
    (c) the amino acid sequence encoded by the cDNA insert of clone rd8106 deposited under accession number ATCC 98835;
  • [0689]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:38. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a protein comprising a fragment of the amino add sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.
  • [0690]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0691]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39;
  • [0692]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080;
  • [0693]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cf851 deposited under accession number ATCC 98850;
  • [0694]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cf851 deposited under accession number ATCC 98850;
  • [0695]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cf851 deposited under accession number ATCC 98850;
  • [0696]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cf851 deposited under accession number ATCC 98850;
  • [0697]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40;
  • [0698]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;
  • [0699]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0700]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0701]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0702]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:39.
  • [0703]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080; the nucleotide sequence of the full-length protein coding sequence of clone cf851 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone cf851 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cf851 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.
  • [0704]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:39.
  • [0705]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0706]
    (a) a process comprising the steps of:
  • [0707]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0708]
    (aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:39; and
  • [0709]
    (ab) the nucleotide sequence of the cDNA insert of clone cf851 deposited under accession number ATCC 98850;
  • [0710]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0711]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0712]
    (b) a process comprising the steps of:
  • [0713]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0714]
    (ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:39; and
  • [0715]
    (bb) the nucleotide sequence of the cDNA insert of clone cf851 deposited under accession number ATCC 98850;
  • [0716]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0717]
    (iii) amplifying human DNA sequences; and
  • [0718]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0719]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:39 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:39, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080.
  • [0720]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0721]
    (a) the amino acid sequence of SEQ ID NO:40;
  • [0722]
    (b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and
  • [0723]
    (c) the amino acid sequence encoded by the cDNA insert of clone cf851 deposited under accession number ATCC 98850;
  • [0724]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.
  • [0725]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0726]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
  • [0727]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348;
  • [0728]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348;
  • [0729]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd50418 deposited under accession number ATCC 98850;
  • [0730]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
  • [0731]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd50418 deposited under accession number ATCC 98850;
  • [0732]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
  • [0733]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
  • [0734]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;
  • [0735]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0736]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0737]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0738]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:41.
  • [0739]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348; the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348; the nucleotide sequence of the full-length protein coding sequence of clone dd50418 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone dd50418 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dd50418 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.
  • [0740]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.
  • [0741]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0742]
    (a) a process comprising the steps of:
  • [0743]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0744]
    (aa) SEQ ID NO:41, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:41; and
  • [0745]
    (ab) the nucleotide sequence of the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
  • [0746]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0747]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0748]
    (b) a process comprising the steps of:
  • [0749]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0750]
    (ba) SEQ ID NO:41, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:41; and
  • [0751]
    (bb) the nucleotide sequence of the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
  • [0752]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0753]
    (iii) amplifying human DNA sequences; and
  • [0754]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0755]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:41, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348.
  • [0756]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0757]
    (a) the amino acid sequence of SEQ ID NO:42;
  • [0758]
    (b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and
  • [0759]
    (c) the amino acid sequence encoded by the cDNA insert of clone dd50418 deposited under accession number ATCC 98850;
  • [0760]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.
  • [0761]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0762]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;
  • [0763]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386;
  • [0764]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone np263 deposited under accession number ATCC 98850;
  • [0765]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone np263 deposited under accession number ATCC 98850;
  • [0766]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone np263 deposited under accession number ATCC 98850;
  • [0767]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone np263 deposited under accession number ATCC 98850;
  • [0768]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;
  • [0769]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;
  • [0770]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0771]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0772]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0773]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:43.
  • [0774]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386; the nucleotide sequence of the full-length protein coding sequence of clone np263 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone np263 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone np263 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.
  • [0775]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:43.
  • [0776]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0777]
    (a) a process comprising the steps of:
  • [0778]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0779]
    (aa) SEQ ID NO:43, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:43; and
  • [0780]
    (ab) the nucleotide sequence of the cDNA insert of done np263 deposited under accession number ATCC 98850;
  • [0781]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0782]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0783]
    (b) a process comprising the steps of:
  • [0784]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0785]
    (ba) SEQ ID NO:43, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:43; and
  • [0786]
    (bb) the nucleotide sequence of the cDNA insert of clone np263 deposited under accession number ATCC 98850;
  • [0787]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0788]
    (iii) amplifying human DNA sequences; and
  • [0789]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0790]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:43, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386.
  • [0791]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0792]
    (a) the amino acid sequence of SEQ ID NO:44;
  • [0793]
    (b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and
  • [0794]
    (c) the amino acid sequence encoded by the cDNA insert of clone np263 deposited under accession number ATCC 98850;
  • [0795]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.
  • [0796]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0797]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45;
  • [0798]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515;
  • [0799]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm41212 deposited under accession number ATCC 98850;
  • [0800]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm41212 deposited under accession number ATCC 98850;
  • [0801]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pm41212 deposited under accession number ATCC 98850;
  • [0802]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm41212 deposited under accession number ATCC 98850;
  • [0803]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:46;
  • [0804]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;
  • [0805]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [0806]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [0807]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [0808]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:45.
  • [0809]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515; the nucleotide sequence of the full-length protein coding sequence of clone pm41212 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pm41212 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm41212 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 571 to amino acid 580 of SEQ ID NO:46.
  • [0810]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:45.
  • [0811]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0812]
    (a) a process comprising the steps of:
  • [0813]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0814]
    (aa) SEQ ID NO:45, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:45; and
  • [0815]
    (ab) the nucleotide sequence of the cDNA insert of clone pm41212 deposited under accession number ATCC 98850;
  • [0816]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0817]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0818]
    (b) a process comprising the steps of:
  • [0819]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0820]
    (ba) SEQ ID NO:45, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:45; and
  • [0821]
    (bb) the nucleotide sequence of the cDNA insert of clone pm41212 deposited under accession number ATCC 98850;
  • [0822]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0823]
    (iii) amplifying human DNA sequences; and
  • [0824]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0825]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:45, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515.
  • [0826]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0827]
    (a) the amino acid sequence of SEQ ID NO:46;
  • [0828]
    (b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and
  • [0829]
    (c) the amino acid sequence encoded by the cDNA insert of clone pm41212 deposited under accession number ATCC 98850;
  • [0830]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 571 to amino acid 580 of SEQ ID NO:46.
  • [0831]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0832]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47;
  • [0833]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780;
  • [0834]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780;
  • [0835]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm4213 deposited under accession number ATCC 98850;
  • [0836]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm4213 deposited under accession number ATCC 98850;
  • [0837]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pm4213 deposited under accession number ATCC 98850;
  • [0838]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm4213 deposited under accession number ATCC 98850;
  • [0839]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48;
  • [0840]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;
  • [0841]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0842]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0843]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0844]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:47.
  • [0845]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780; the nucleotide sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780; the nucleotide sequence of the funll-length protein coding sequence of clone pm4213 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pm4213 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm4213 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.
  • [0846]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:47.
  • [0847]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0848]
    (a) a process comprising the steps of:
  • [0849]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0850]
    (aa) SEQ ID NO:47, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:47; and
  • [0851]
    (ab) the nucleotide sequence of the cDNA insert of done pm4213 deposited under accession number ATCC 98850;
  • [0852]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0853]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0854]
    (b) a process comprising the steps of:
  • [0855]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0856]
    (ba) SEQ ID NO:47, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:47; and
  • [0857]
    (bb) the nucleotide sequence of the cDNA insert of clone pm4213 deposited under accession number ATCC 98850;
  • [0858]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0859]
    (iii) amplifying human DNA sequences; and
  • [0860]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0861]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:47, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780.
  • [0862]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0863]
    (a) the amino acid sequence of SEQ ID NO:48;
  • [0864]
    (b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and
  • [0865]
    (c) the amino acid sequence encoded by the cDNA insert of clone pm4213 deposited under accession number ATCC 98850;
  • [0866]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.
  • [0867]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0868]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49;
  • [0869]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486;
  • [0870]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486;
  • [0871]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pv61 deposited under accession number ATCC 98850;
  • [0872]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pv61 deposited under accession number ATCC 98850;
  • [0873]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pv61 deposited under accession number ATCC 98850;
  • [0874]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pv61 deposited under accession number ATCC 98850;
  • [0875]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:50;
  • [0876]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;
  • [0877]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0878]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0879]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0880]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:49.
  • [0881]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486; the nucleotide sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486; the nucleotide sequence of the full-length protein coding sequence of clone pv61 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pv61 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv61 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:50.
  • [0882]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:49.
  • [0883]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0884]
    (a) a process comprising the steps of:
  • [0885]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0886]
    (aa) SEQ ID NO:49, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:49; and
  • [0887]
    (ab) the nucleotide sequence of the cDNA insert of clone pv61 deposited under accession number ATCC 98850;
  • [0888]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0889]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0890]
    (b) a process comprising the steps of:
  • [0891]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0892]
    (ba) SEQ ID NO:49, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:49; and
  • [0893]
    (bb) the nucleotide sequence of the cDNA insert of clone pv61 deposited under accession number ATCC 98850;
  • [0894]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0895]
    (iii) amplifying human DNA sequences; and
  • [0896]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0897]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:49 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:49, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486.
  • [0898]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0899]
    (a) the amino acid sequence of SEQ ID NO:50;
  • [0900]
    (b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and
  • [0901]
    (c) the amino acid sequence encoded by the cDNA insert of clone pv61 deposited under accession number ATCC 98850;
  • [0902]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:50. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:50.
  • [0903]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0904]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51;
  • [0905]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783;
  • [0906]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783;
  • [0907]
    (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938;
  • [0908]
    (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qs143 deposited under accession number ATCC 98850;
  • [0909]
    (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
  • [0910]
    (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of done qs143 deposited under accession number ATCC 98850;
  • [0911]
    (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
  • [0912]
    (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52;
  • [0913]
    (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;
  • [0914]
    (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
  • [0915]
    (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above;
  • [0916]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
  • [0917]
    (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:51.
  • [0918]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783; the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783; the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938; the nucleotide sequence of the full-length protein coding sequence of clone qs143 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone qs143 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qs143 deposited under accession number ATCC 98850. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.
  • [0919]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:51.
  • [0920]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0921]
    (a) a process comprising the steps of:
  • [0922]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0923]
    (aa) SEQ ID NO:51, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:51; and
  • [0924]
    (ab) the nucleotide sequence of the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
  • [0925]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0926]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0927]
    (b) a process comprising the steps of:
  • [0928]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0929]
    (ba) SEQ ID NO:51, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:51; and
  • [0930]
    (bb) the nucleotide sequence of the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
  • [0931]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0932]
    (iii) amplifying human DNA sequences; and
  • [0933]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0934]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:51 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:51, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938.
  • [0935]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0936]
    (a) the amino acid sequence of SEQ ID NO:52;
  • [0937]
    (b) the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135;
  • [0938]
    (c) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and
  • [0939]
    (d) the amino acid sequence encoded by the cDNA insert of clone qs143 deposited under accession number ATCC 98850;
  • [0940]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:52 or the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.
  • [0941]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0942]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53;
  • [0943]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843;
  • [0944]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843;
  • [0945]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qy3389 deposited under accession number ATCC 98850;
  • [0946]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy3389 deposited under accession number ATCC 98850;
  • [0947]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qy3389 deposited under accession number ATCC 98850;
  • [0948]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qy3389 deposited under accession number ATCC 98850;
  • [0949]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54;
  • [0950]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;
  • [0951]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0952]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0953]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0954]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:53.
  • [0955]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843; the nucleotide sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843; the nucleotide sequence of the full-length protein coding sequence of clone qy3389 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone qy3389 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy3389 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.
  • [0956]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:53.
  • [0957]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0958]
    (a) a process comprising the steps of:
  • [0959]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0960]
    (aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:53; and
  • [0961]
    (ab) the nucleotide sequence of the cDNA insert of clone qy3389 deposited under accession number ATCC 98850;
  • [0962]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0963]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [0964]
    (b) a process comprising the steps of:
  • [0965]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0966]
    (ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:53; and
  • [0967]
    (bb) the nucleotide sequence of the cDNA insert of clone qy3389 deposited under accession number ATCC 98850;
  • [0968]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [0969]
    (iii) amplifying human DNA sequences; and
  • [0970]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [0971]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:53 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:53, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843.
  • [0972]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [0973]
    (a) the amino acid sequence of SEQ ID NO:54;
  • [0974]
    (b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and
  • [0975]
    (c) the amino acid sequence encoded by the cDNA insert of clone qy3389 deposited under accession number ATCC 98850;
  • [0976]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.
  • [0977]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [0978]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55;
  • [0979]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906;
  • [0980]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906;
  • [0981]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rc581 deposited under accession number ATCC 98850;
  • [0982]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rc581 deposited under accession number ATCC 98850;
  • [0983]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rc581 deposited under accession number ATCC 98850;
  • [0984]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rc581 deposited under accession number ATCC 98850;
  • [0985]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:56;
  • [0986]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;
  • [0987]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [0988]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [0989]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [0990]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.
  • [0991]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906; the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906; the nucleotide sequence of the full-length protein coding sequence of clone rc581 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rc581 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rc581 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:56.
  • [0992]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:55.
  • [0993]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [0994]
    (a) a process comprising the steps of:
  • [0995]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [0996]
    (aa) SEQ ID NO:55, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:55; and
  • [0997]
    (ab) the nucleotide sequence of the cDNA insert of done rc581 deposited under accession number ATCC 98850;
  • [0998]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [0999]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and =(b) a process comprising the steps of:
  • [1000]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1001]
    (ba) SEQ ID NO:55, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:55; and
  • [1002]
    (bb) the nucleotide sequence of the cDNA insert of clone rc581 deposited under accession number ATCC 98850;
  • [1003]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1004]
    (iii) amplifying human DNA sequences; and
  • [1005]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1006]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:55, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:55. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906.
  • [1007]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1008]
    (a) the amino acid sequence of SEQ ID NO:56;
  • [1009]
    (b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and
  • [1010]
    (c) the amino acid sequence encoded by the cDNA insert of clone rc581 deposited under accession number ATCC 98850;
  • [1011]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:56.
  • [1012]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1013]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57;
  • [1014]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973;
  • [1015]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd2325 deposited under accession number ATCC 98850;
  • [1016]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd2325 deposited under accession number ATCC 98850;
  • [1017]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd2325 deposited under accession number ATCC 98850;
  • [1018]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd2325 deposited under accession number ATCC 98850;
  • [1019]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:58;
  • [1020]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:58;
  • [1021]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1022]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1023]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1024]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:57.
  • [1025]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973; the nucleotide sequence of the full-length protein coding sequence of clone rd2325 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rd2325 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done rd2325 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.
  • [1026]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:57.
  • [1027]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1028]
    (a) a process comprising the steps of:
  • [1029]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1030]
    (aa) SEQ ID NO:57, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:57; and
  • [1031]
    (ab) the nucleotide sequence of the cDNA insert of clone rd2325 deposited under accession number ATCC 98850;
  • [1032]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1033]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1034]
    (b) a process comprising the steps of:
  • [1035]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1036]
    (ba) SEQ ID NO:57, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:57; and
  • [1037]
    (bb) the nucleotide sequence of the cDNA insert of clone rd2325 deposited under accession number ATCC 98850;
  • [1038]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1039]
    (iii) amplifying human DNA sequences; and
  • [1040]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1041]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:57 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:57, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973.
  • [1042]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1043]
    (a) the amino acid sequence of SEQ ID NO:58;
  • [1044]
    (b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and
  • [1045]
    (c) the amino acid sequence encoded by the cDNA insert of clone rd2325 deposited under accession number ATCC 98850;
  • [1046]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:58. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.
  • [1047]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1048]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59;
  • [1049]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596;
  • [1050]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ck21312 deposited under accession number ATCC 98918;
  • [1051]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ck21312 deposited under accession number ATCC 98918;
  • [1052]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ck21312 deposited under accession number ATCC 98918;
  • [1053]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ck21312 deposited under accession number ATCC 98918;
  • [1054]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:60;
  • [1055]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;
  • [1056]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1057]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1058]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1059]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:59.
  • [1060]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596; the nucleotide sequence of the full-length protein coding sequence of clone ck21312 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone ck21312 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ck21312 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.
  • [1061]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:59.
  • [1062]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1063]
    (a) a process comprising the steps of:
  • [1064]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1065]
    (aa) SEQ ID NO:59, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:59; and
  • [1066]
    (ab) the nucleotide sequence of the cDNA insert of clone ck21312 deposited under accession number ATCC 98918; 115 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1067]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1068]
    (b) a process comprising the steps of:
  • [1069]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1070]
    (ba) SEQ ID NO:59, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:59; and
  • [1071]
    (bb) the nucleotide sequence of the cDNA insert of clone ck21312 deposited under accession number ATCC 98918;
  • [1072]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1073]
    (iii) amplifying human DNA sequences; and
  • [1074]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1075]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:59 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:59, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:59. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596.
  • [1076]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1077]
    (a) the amino acid sequence of SEQ ID NO:60;
  • [1078]
    (b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and
  • [1079]
    (c) the amino acid sequence encoded by the cDNA insert of clone ck21312 deposited under accession number ATCC 98918;
  • [1080]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.
  • [1081]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1082]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61;
  • [1083]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750;
  • [1084]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pg1951 deposited under accession number ATCC 98918;
  • [1085]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pg1951 deposited under accession number ATCC 98918;
  • [1086]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pg1951 deposited under accession number ATCC 98918;
  • [1087]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pg1951 deposited under accession number ATCC 98918;
  • [1088]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:62;
  • [1089]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;
  • [1090]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1091]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1092]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1093]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:61.
  • [1094]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750; the nucleotide sequence of the full-length protein coding sequence of clone pg1951 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone pg1951 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pg1951 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.
  • [1095]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:61.
  • [1096]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1097]
    (a) a process comprising the steps of:
  • [1098]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1099]
    (aa) SEQ ID NO:61, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:61; and
  • [1100]
    (ab) the nucleotide sequence of the cDNA insert of clone pg1951 deposited under accession number ATCC 98918;
  • [1101]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1102]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1103]
    (b) a process comprising the steps of:
  • [1104]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1105]
    (ba) SEQ ID NO:61, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:61; and
  • [1106]
    (bb) the nucleotide sequence of the cDNA insert of clone pg1951 deposited under accession number ATCC 98918;
  • [1107]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1108]
    (iii) amplifying human DNA sequences; and
  • [1109]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1110]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:61 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:61, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750.
  • [1111]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1112]
    (a) the amino acid sequence of SEQ ID NO:62;
  • [1113]
    (b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and
  • [1114]
    (c) the amino acid sequence encoded by the cDNA insert of clone pg1951 deposited under accession number ATCC 98918;
  • [1115]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:62. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.
  • [1116]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1117]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63;
  • [1118]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440;
  • [1119]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440;
  • [1120]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pw4605 deposited under accession number ATCC 98918;
  • [1121]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pw4605 deposited under accession number ATCC 98918;
  • [1122]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pw4605 deposited under accession number ATCC 98918;
  • [1123]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pw4605 deposited under accession number ATCC 98918;
  • [1124]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:64;
  • [1125]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;
  • [1126]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1127]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1128]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1129]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:63.
  • [1130]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440; the nucleotide sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440; the nucleotide sequence of the full-length protein coding sequence of clone pw4605 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone pw4605 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pw4605 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.
  • [1131]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:63.
  • [1132]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1133]
    (a) a process comprising the steps of:
  • [1134]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1135]
    (aa) SEQ ID NO:63, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:63; and
  • [1136]
    (ab) the nucleotide sequence of the cDNA insert of clone pw4605 deposited under accession number ATCC 98918;
  • [1137]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1138]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1139]
    (b) a process comprising the steps of:
  • [1140]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1141]
    (ba) SEQ ID NO:63, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:63; and
  • [1142]
    (bb) the nucleotide sequence of the cDNA insert of clone pw4605 deposited under accession number ATCC 98918;
  • [1143]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1144]
    (iii) amplifying human DNA sequences; and
  • [1145]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1146]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:63 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:63, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:63. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440.
  • [1147]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1148]
    (a) the amino acid sequence of SEQ ID NO:64;
  • [1149]
    (b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and
  • [1150]
    (c) the amino acid sequence encoded by the cDNA insert of clone pw4605 deposited under accession number ATCC 98918;
  • [1151]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:64. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.
  • [1152]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1153]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65;
  • [1154]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356;
  • [1155]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356;
  • [1156]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qa1361 deposited under accession number ATCC 98918;
  • [1157]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qa1361 deposited under accession number ATCC 98918;
  • [1158]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qa1361 deposited under accession number ATCC 98918;
  • [1159]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qa1361 deposited under accession number ATCC 98918;
  • [1160]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:66;
  • [1161]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:66;
  • [1162]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1163]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1164]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1165]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:65.
  • [1166]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356; the nucleotide sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356; the nucleotide sequence of the full-length protein coding sequence of clone qa1361 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone qa1361 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qa1361 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 213 to amino acid 222 of SEQ ID NO:66.
  • [1167]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:65.
  • [1168]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1169]
    (a) a process comprising the steps of:
  • [1170]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1171]
    (aa) SEQ ID NO:65; and
  • [1172]
    (ab) the nucleotide sequence of the cDNA insert of clone qa1361 deposited under accession number ATCC 98918;
  • [1173]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1174]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1175]
    (b) a process comprising the steps of:
  • [1176]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1177]
    (ba) SEQ ID NO:65; and
  • [1178]
    (bb) the nucleotide sequence of the cDNA insert of clone qa1361 deposited under accession number ATCC 98918;
  • [1179]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1180]
    (iii) amplifying human DNA sequences; and
  • [1181]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1182]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:65 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:65. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356.
  • [1183]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • [1184]
    (a) the amino acid sequence of SEQ ID NO:66;
  • [1185]
    (b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and
  • [1186]
    (c) the amino acid sequence encoded by the cDNA insert of clone qa1361 deposited under accession number ATCC 98918;
  • [1187]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:66. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 213 to amino acid 222 of SEQ ID NO:66.
  • [1188]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1189]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67;
  • [1190]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624;
  • [1191]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624;
  • [1192]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qy12612 deposited under accession number ATCC 98918;
  • [1193]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy12612 deposited under accession number ATCC 98918;
  • [1194]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qy12612 deposited under accession number ATCC 98918;
  • [1195]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qy12612 deposited under accession number ATCC 98918;
  • [1196]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:68;
  • [1197]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:68;
  • [1198]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1199]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1200]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1201]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:67.
  • [1202]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624; the nucleotide sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624; the nucleotide sequence of the full-length protein coding sequence of clone qy12612 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone qy12612 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy12612 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:68, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 231 to amino acid 240 of SEQ ID NO:68.
  • [1203]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:67.
  • [1204]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1205]
    (a) a process comprising the steps of:
  • [1206]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1207]
    (aa) SEQ ID NO:67, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:67; and
  • [1208]
    (ab) the nucleotide sequence of the cDNA insert of clone qy12612 deposited under accession number ATCC 98918;
  • [1209]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1210]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1211]
    (b) a process comprising the steps of:
  • [1212]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1213]
    (ba) SEQ ID NO:67, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:67; and
  • [1214]
    (bb) the nucleotide sequence of the cDNA insert of clone qy12612 deposited under accession number ATCC 98918;
  • [1215]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1216]
    (iii) amplifying human DNA sequences; and
  • [1217]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1218]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:67 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:67, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:67. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624.
  • [1219]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1220]
    (a) the amino acid sequence of SEQ ID NO:68;
  • [1221]
    (b) a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68; and
  • [1222]
    (c) the amino acid sequence encoded by the cDNA insert of clone qy12612 deposited under accession number ATCC 98918;
  • [1223]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:68. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 231 to amino acid 240 of SEQ ID NO:68.
  • [1224]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1225]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69;
  • [1226]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817;
  • [1227]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd4324 deposited under accession number ATCC 98918;
  • [1228]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd4324 deposited under accession number ATCC 98918;
  • [1229]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd4324 deposited under accession number ATCC 98918;
  • [1230]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd4324 deposited under accession number ATCC 98918;
  • [1231]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:70;
  • [1232]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:70;
  • [1233]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1234]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1235]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1236]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:69.
  • [1237]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817; the nucleotide sequence of the full-length protein coding sequence of clone rd4324 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone rd4324 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd4324 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:70.
  • [1238]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:69.
  • [1239]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1240]
    (a) a process comprising the steps of:
  • [1241]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1242]
    (aa) SEQ ID NO:69, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:69; and
  • [1243]
    (ab) the nucleotide sequence of the cDNA insert of clone rd4324 deposited under accession number ATCC 98918;
  • [1244]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1245]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1246]
    (b) a process comprising the steps of:
  • [1247]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1248]
    (ba) SEQ ID NO:69, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:69; and
  • [1249]
    (bb) the nucleotide sequence of the cDNA insert of clone rd4324 deposited under accession number ATCC 98918;
  • [1250]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1251]
    (iii) amplifying human DNA sequences; and
  • [1252]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1253]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:69 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:69, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:69. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817.
  • [1254]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1255]
    (a) the amino acid sequence of SEQ ID NO:70;
  • [1256]
    (b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70; and
  • [1257]
    (c) the amino acid sequence encoded by the cDNA insert of clone rd4324 deposited under accession number ATCC 98918;
  • [1258]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:70. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:70.
  • [1259]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1260]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71;
  • [1261]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195;
  • [1262]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195;
  • [1263]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rb78914 deposited under accession number ATCC 207004;
  • [1264]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rb78914 deposited under accession number ATCC 207004;
  • [1265]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rb78914 deposited under accession number ATCC 207004;
  • [1266]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rb78914 deposited under accession number ATCC 207004;
  • [1267]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:72;
  • [1268]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:72;
  • [1269]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1270]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1271]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1272]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:71.
  • [1273]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195; the nucleotide sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195; the nucleotide sequence of the full-length protein coding sequence of clone rb78914 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone rb78914 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rb78914 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:72.
  • [1274]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:71.
  • [1275]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1276]
    (a) a process comprising the steps of:
  • [1277]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1278]
    (aa) SEQ ID NO:71, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:71; and
  • [1279]
    (ab) the nucleotide sequence of the cDNA insert of clone rb78914 deposited under accession number ATCC 207004;
  • [1280]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1281]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1282]
    (b) a process comprising the steps of:
  • [1283]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1284]
    (ba) SEQ ID NO:71, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:71; and
  • [1285]
    (bb) the nucleotide sequence of the cDNA insert of clone rb78914 deposited under accession number ATCC 207004;
  • [1286]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1287]
    (iii) amplifying human DNA sequences; and
  • [1288]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1289]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:71 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:71, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:71. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195.
  • [1290]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1291]
    (a) the amino acid sequence of SEQ ID NO:72;
  • [1292]
    (b) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; and
  • [1293]
    (c) the amino acid sequence encoded by the cDNA insert of clone rb78914 deposited under accession number ATCC 207004;
  • [1294]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:72. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:72.
  • [1295]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1296]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73;
  • [1297]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374;
  • [1298]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374;
  • [1299]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yd1371 deposited under accession number ATCC 207004;
  • [1300]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yd1371 deposited under accession number ATCC 207004;
  • [1301]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yd1371 deposited under accession number ATCC 207004;
  • [1302]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yd1371 deposited under accession number ATCC 207004;
  • [1303]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:74;
  • [1304]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:74;
  • [1305]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1306]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1307]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1308]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:73.
  • [1309]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374; the nucleotide sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374; the nucleotide sequence of the full-length protein coding sequence of clone yd1371 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yd1371 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yd1371 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:74.
  • [1310]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:73.
  • [1311]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1312]
    (a) a process comprising the steps of:
  • [1313]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1314]
    (aa) SEQ ID NO:73, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:73; and
  • [1315]
    (ab) the nucleotide sequence of the cDNA insert of clone yd1371 deposited under accession number ATCC 207004;
  • [1316]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1317]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1318]
    (b) a process comprising the steps of:
  • [1319]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1320]
    (ba) SEQ ID NO:73, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:73; and
  • [1321]
    (bb) the nucleotide sequence of the cDNA insert of clone yd1371 deposited under accession number ATCC 207004;
  • [1322]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1323]
    (iii) amplifying human DNA sequences; and
  • [1324]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1325]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:73 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:73, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:73. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374.
  • [1326]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1327]
    (a) the amino acid sequence of SEQ ID NO:74;
  • [1328]
    (b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; and
  • [1329]
    (c) the amino acid sequence encoded by the cDNA insert of done yd1371 deposited under accession number ATCC 207004;
  • [1330]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:74. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:74.
  • [1331]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1332]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75;
  • [1333]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343;
  • [1334]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343;
  • [1335]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yd2181 deposited under accession number ATCC 207004;
  • [1336]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yd2181 deposited under accession number ATCC 207004;
  • [1337]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yd2181 deposited under accession number ATCC 207004;
  • [1338]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yd2181 deposited under accession number ATCC 207004;
  • [1339]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:76;
  • [1340]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;
  • [1341]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1342]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1343]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1344]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:75.
  • [1345]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343; the nucleotide sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343; the nucleotide sequence of the full-length protein coding sequence of clone yd2181 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yd2181 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yd2181 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:76.
  • [1346]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:75.
  • [1347]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1348]
    (a) a process comprising the steps of:
  • [1349]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1350]
    (aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:75; and
  • [1351]
    (ab) the nucleotide sequence of the cDNA insert of clone yd2181 deposited under accession number ATCC 207004;
  • [1352]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1353]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1354]
    (b) a process comprising the steps of:
  • [1355]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1356]
    (ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:75; and
  • [1357]
    (bb) the nucleotide sequence of the cDNA insert of clone yd2181 deposited under accession number ATCC 207004;
  • [1358]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1359]
    (iii) amplifying human DNA sequences; and
  • [1360]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1361]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:75 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:75, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343.
  • [1362]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1363]
    (a) the amino acid sequence of SEQ ID NO:76;
  • [1364]
    (b) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and
  • [1365]
    (c) the amino acid sequence encoded by the cDNA insert of clone yd2181 deposited under accession number ATCC 207004;
  • [1366]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:76. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:76.
  • [1367]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1368]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77;
  • [1369]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679;
  • [1370]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye111 deposited under accession number ATCC 207004;
  • [1371]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye111 deposited under accession number ATCC 207004;
  • [1372]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye111 deposited under accession number ATCC 207004;
  • [1373]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye111 deposited under accession number ATCC 207004;
  • [1374]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78;
  • [1375]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;
  • [1376]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1377]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1378]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1379]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:77.
  • [1380]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679; the nucleotide sequence of the full-length protein coding sequence of clone ye111 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye111 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye111 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 261 to amino acid 270 of SEQ ID NO:78.
  • [1381]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:77.
  • [1382]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1383]
    (a) a process comprising the steps of:
  • [1384]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1385]
    (aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:77; and
  • [1386]
    (ab) the nucleotide sequence of the cDNA insert of clone ye111 deposited under accession number ATCC 207004;
  • [1387]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1388]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1389]
    (b) a process comprising the steps of:
  • [1390]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1391]
    (ba) SEQ ID NO:77, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:77; and
  • [1392]
    (bb) the nucleotide sequence of the cDNA insert of clone ye111 deposited under accession number ATCC 207004;
  • [1393]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1394]
    (iii) amplifying human DNA sequences; and
  • [1395]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1396]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:77 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:77, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679.
  • [1397]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1398]
    (a) the amino acid sequence of SEQ ID NO:78;
  • [1399]
    (b) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and
  • [1400]
    (c) the amino acid sequence encoded by the cDNA insert of clone ye111 deposited under accession number ATCC 207004;
  • [1401]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:78. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 261 to amino acid 270 of SEQ ID NO:78.
  • [1402]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1403]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79;
  • [1404]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646;
  • [1405]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646;
  • [1406]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye721 deposited under accession number ATCC 207004;
  • [1407]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye721 deposited under accession number ATCC 207004;
  • [1408]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye721 deposited under accession number ATCC 207004;
  • [1409]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye721 deposited under accession number ATCC 207004;
  • [1410]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:80;
  • [1411]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;
  • [1412]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1413]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1414]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1415]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:79.
  • [1416]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646; the nucleotide sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646; the nucleotide sequence of the full-length protein coding sequence of clone ye721 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye721 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye721 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 257 to amino acid 266 of SEQ ID NO:80.
  • [1417]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:79.
  • [1418]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1419]
    (a) a process comprising the steps of:
  • [1420]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1421]
    (aa) SEQ ID NO:79, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:79; and
  • [1422]
    (ab) the nucleotide sequence of the cDNA insert of clone ye721 deposited under accession number ATCC 207004;
  • [1423]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1424]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1425]
    (b) a process comprising the steps of:
  • [1426]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1427]
    (ba) SEQ ID NO:79, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:79; and
  • [1428]
    (bb) the nucleotide sequence of the cDNA insert of clone ye721 deposited under accession number ATCC 207004;
  • [1429]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1430]
    (iii) amplifying human DNA sequences; and
  • [1431]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1432]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:79 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:79, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646.
  • [1433]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1434]
    (a) the amino acid sequence of SEQ ID NO:80;
  • [1435]
    (b) a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; and
  • [1436]
    (c) the amino acid sequence encoded by the cDNA insert of clone ye721 deposited under accession number ATCC 207004;
  • [1437]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 257 to amino acid 266 of SEQ ID NO:80.
  • [1438]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1439]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81;
  • [1440]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423;
  • [1441]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423;
  • [1442]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye781 deposited under accession number ATCC 207004;
  • [1443]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye781 deposited under accession number ATCC 207004;
  • [1444]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye781 deposited under accession number ATCC 207004;
  • [1445]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye781 deposited under accession number ATCC 207004;
  • [1446]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:82;
  • [1447]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:82;
  • [1448]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1449]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1450]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1451]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:81.
  • [1452]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423; the nucleotide sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423; the nucleotide sequence of the full-length protein coding sequence of clone ye781 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye781 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye781 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:82.
  • [1453]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:81.
  • [1454]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1455]
    (a) a process comprising the steps of:
  • [1456]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1457]
    (aa) SEQ ID NO:81, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:81; and
  • [1458]
    (ab) the nucleotide sequence of the cDNA insert of clone ye781 deposited under accession number ATCC 207004;
  • [1459]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1460]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1461]
    (b) a process comprising the steps of:
  • [1462]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1463]
    (ba) SEQ ID NO:81, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:81; and
  • [1464]
    (bb) the nucleotide sequence of the cDNA insert of clone ye781 deposited under accession number ATCC 207004;
  • [1465]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1466]
    (iii) amplifying human DNA sequences; and
  • [1467]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1468]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:81 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:81, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:81. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423.
  • [1469]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1470]
    (a) the amino acid sequence of SEQ ID NO:82;
  • [1471]
    (b) a fragment of the amino acid sequence of SEQ ID NO:82, the fragment comprising eight contiguous amino acids of SEQ ID NO:82; and
  • [1472]
    (c) the amino acid sequence encoded by the cDNA insert of clone ye781 deposited under accession number ATCC 207004;
  • [1473]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:82. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:82.
  • [1474]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1475]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83;
  • [1476]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321;
  • [1477]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321;
  • [1478]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye901 deposited under accession number ATCC 207004;
  • [1479]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye901 deposited under accession number ATCC 207004;
  • [1480]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye901 deposited under accession number ATCC 207004;
  • [1481]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye901 deposited under accession number ATCC 207004;
  • [1482]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:84;
  • [1483]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:84;
  • [1484]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1485]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1486]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1487]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:83.
  • [1488]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321; the nucleotide sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321; the nucleotide sequence of the full-length protein coding sequence of clone ye901 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye901 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye901 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising the amino acid sequence from amino acid 186 to amino acid 195 of SEQ ID NO:84.
  • [1489]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:83.
  • [1490]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1491]
    (a) a process comprising the steps of:
  • [1492]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1493]
    (aa) SEQ ID NO:83, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:83; and
  • [1494]
    (ab) the nucleotide sequence of the cDNA insert of clone ye901 deposited under accession number ATCC 207004;
  • [1495]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1496]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1497]
    (b) a process comprising the steps of:
  • [1498]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1499]
    (ba) SEQ ID NO:83, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:83; and
  • [1500]
    (bb) the nucleotide sequence of the cDNA insert of clone ye901 deposited under accession number ATCC 207004;
  • [1501]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1502]
    (iii) amplifying human DNA sequences; and
  • [1503]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1504]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:83 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:83, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:83. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321.
  • [1505]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1506]
    (a) the amino acid sequence of SEQ ID NO:84;
  • [1507]
    (b) a fragment of the amino acid sequence of SEQ ID NO:84, the fragment comprising eight contiguous amino acids of SEQ ID NO:84; and
  • [1508]
    (c) the amino acid sequence encoded by the cDNA insert of clone ye901 deposited under accession number ATCC 207004;
  • [1509]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:84. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising the amino acid sequence from amino acid 186 to amino acid 195 of SEQ ID NO:84.
  • [1510]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1511]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85;
  • [1512]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605;
  • [1513]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yi621 deposited under accession number ATCC 207004;
  • [1514]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yi621 deposited under accession number ATCC 207004;
  • [1515]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yi621 deposited under accession number ATCC 207004;
  • [1516]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yi621 deposited under accession number ATCC 207004;
  • [1517]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:86;
  • [1518]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:86;
  • [1519]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1520]
    (j) a polynucleotide which encodes a spedes homologue of the protein of (g) or (h) above;
  • [1521]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1522]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:85.
  • [1523]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605; the nucleotide sequence of the full-length protein coding sequence of clone yi621 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yi621 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yi621 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:86, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:86.
  • [1524]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:85.
  • [1525]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1526]
    (a) a process comprising the steps of:
  • [1527]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1528]
    (aa) SEQ ID NO:85, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:85; and
  • [1529]
    (ab) the nucleotide sequence of the cDNA insert of clone yi621 deposited under accession number ATCC 207004;
  • [1530]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1531]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1532]
    (b) a process comprising the steps of:
  • [1533]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1534]
    (ba) SEQ ID NO:85, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:85; and
  • [1535]
    (bb) the nucleotide sequence of the cDNA insert of clone yi621 deposited under accession number ATCC 207004;
  • [1536]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1537]
    (iii) amplifying human DNA sequences; and
  • [1538]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1539]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:85 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:85, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:85. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605.
  • [1540]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1541]
    (a) the amino acid sequence of SEQ ID NO:86;
  • [1542]
    (b) a fragment of the amino acid sequence of SEQ ID NO:86, the fragment comprising eight contiguous amino acids of SEQ ID NO:86; and
  • [1543]
    (c) the amino acid sequence encoded by the cDNA insert of clone yi621 deposited under accession number ATCC 207004;
  • [1544]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:86. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:86, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:86.
  • [1545]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1546]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87;
  • [1547]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798;
  • [1548]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798;
  • [1549]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yk781 deposited under accession number ATCC 207004;
  • [1550]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yk781 deposited under accession number ATCC 207004;
  • [1551]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yk781 deposited under accession number ATCC 207004;
  • [1552]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yk781 deposited under accession number ATCC 207004;
  • [1553]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:88;
  • [1554]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:88;
  • [1555]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1556]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1557]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1558]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:87.
  • [1559]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798; the nucleotide sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798; the nucleotide sequence of the full-length protein coding sequence of clone yk781 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yk781 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yk781 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 91 to amino acid 100 of SEQ ID NO:88.
  • [1560]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:87.
  • [1561]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1562]
    (a) a process comprising the steps of:
  • [1563]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1564]
    (aa) SEQ ID NO:87, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:87; and
  • [1565]
    (ab) the nucleotide sequence of the cDNA insert of clone yk781 deposited under accession number ATCC 207004;
  • [1566]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1567]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1568]
    (b) a process comprising the steps of:
  • [1569]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1570]
    (ba) SEQ ID NO:87, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:87; and
  • [1571]
    (bb) the nucleotide sequence of the cDNA insert of clone yk781 deposited under accession number ATCC 207004;
  • [1572]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1573]
    (iii) amplifying human DNA sequences; and
  • [1574]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1575]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:87 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:87, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:87. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798.
  • [1576]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1577]
    (a) the amino acid sequence of SEQ ID NO:88;
  • [1578]
    (b) a fragment of the amino acid sequence of SEQ ID NO:88, the fragment comprising eight contiguous amino acids of SEQ ID NO:88; and
  • [1579]
    (c) the amino acid sequence encoded by the cDNA insert of clone yk781 deposited under accession number ATCC 207004;
  • [1580]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:88. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 91 to amino acid 100 of SEQ ID NO:88.
  • [1581]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1582]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89;
  • [1583]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942;
  • [1584]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942;
  • [1585]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yk2511 deposited under accession number ATCC 207004;
  • [1586]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yk2511 deposited under accession number ATCC 207004;
  • [1587]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yk2511 deposited under accession number ATCC 207004;
  • [1588]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yk2511 deposited under accession number ATCC 207004;
  • [1589]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:90;
  • [1590]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:90;
  • [1591]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1592]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1593]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1594]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:89.
  • [1595]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942; the nucleotide sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942; the nucleotide sequence of the full-length protein coding sequence of clone yk2511 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yk2511 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yk2511 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:90.
  • [1596]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:89.
  • [1597]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1598]
    (a) a process comprising the steps of:
  • [1599]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1600]
    (aa) SEQ ID NO:89, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:89; and
  • [1601]
    (ab) the nucleotide sequence of the cDNA insert of clone yk2511 deposited under accession number ATCC 207004;
  • [1602]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1603]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1604]
    (b) a process comprising the steps of:
  • [1605]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1606]
    (ba) SEQ ID NO:89, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:89; and
  • [1607]
    (bb) the nucleotide sequence of the cDNA insert of clone yk2511 deposited under accession number ATCC 207004;
  • [1608]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1609]
    (iii) amplifying human DNA sequences; and
  • [1610]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1611]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:89 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:89, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:89. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942.
  • [1612]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1613]
    (a) the amino acid sequence of SEQ ID NO:90;
  • [1614]
    (b) a fragment of the amino acid sequence of SEQ ID NO:90, the fragment comprising eight contiguous amino acids of SEQ ID NO:90; and
  • [1615]
    (c) the amino acid sequence encoded by the cDNA insert of clone yk2511 deposited under accession number ATCC 207004;
  • [1616]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:90. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:90.
  • [1617]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1618]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91;
  • [1619]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784;
  • [1620]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yt141 deposited under accession number ATCC 207004;
  • [1621]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yt141 deposited under accession number ATCC 207004;
  • [1622]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yt141 deposited under accession number ATCC 207004;
  • [1623]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yt141 deposited under accession number ATCC 207004;
  • [1624]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:92;
  • [1625]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:92;
  • [1626]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1627]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1628]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1629]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:91.
  • [1630]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784; the nucleotide sequence of the full-length protein coding sequence of clone yt141 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yt141 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yt141 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:92.
  • [1631]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:91.
  • [1632]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1633]
    (a) a process comprising the steps of:
  • [1634]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1635]
    (aa) SEQ ID NO:91, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:91; and
  • [1636]
    (ab) the nucleotide sequence of the cDNA insert of done yt141 deposited under accession number ATCC 207004;
  • [1637]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1638]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1639]
    (b) a process comprising the steps of:
  • [1640]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1641]
    (ba) SEQ ID NO:91, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:91; and
  • [1642]
    (bb) the nucleotide sequence of the cDNA insert of clone yt141 deposited under accession number ATCC 207004;
  • [1643]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1644]
    (iii) amplifying human DNA sequences; and
  • [1645]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1646]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:91 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:91, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:91. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784.
  • [1647]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1648]
    (a) the amino acid sequence of SEQ ID NO:92;
  • [1649]
    (b) a fragment of the amino acid sequence of SEQ ID NO:92, the fragment comprising eight contiguous amino acids of SEQ ID NO:92; and
  • [1650]
    (c) the amino acid sequence encoded by the cDNA insert of clone yt141 deposited under accession number ATCC 207004;
  • [1651]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:92. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:92.
  • [1652]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1653]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93;
  • [1654]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441;
  • [1655]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bf15716 deposited under accession number ATCC 207088;
  • [1656]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bf15716 deposited under accession number ATCC 207088;
  • [1657]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bf15716 deposited under accession number ATCC 207088;
  • [1658]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bf15716 deposited under accession number ATCC 207088;
  • [1659]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:94;
  • [1660]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:94;
  • [1661]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1662]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1663]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1664]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:93.
  • [1665]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441; the nucleotide sequence of the full-length protein coding sequence of clone bf15716 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone bf15716 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bf15716 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:94, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino add 220 to amino acid 229 of SEQ ID NO:94.
  • [1666]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:93.
  • [1667]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1668]
    (a) a process comprising the steps of:
  • [1669]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1670]
    (aa) SEQ ID NO:93, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:93; and
  • [1671]
    (ab) the nucleotide sequence of the cDNA insert of clone bf15716 deposited under accession number ATCC 207088;
  • [1672]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1673]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1674]
    (b) a process comprising the steps of:
  • [1675]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1676]
    (ba) SEQ ID NO:93, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:93; and
  • [1677]
    (bb) the nucleotide sequence of the cDNA insert of clone bf15716 deposited under accession number ATCC 207088;
  • [1678]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1679]
    (iii) amplifying human DNA sequences; and
  • [1680]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1681]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:93 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:93, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:93. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441.
  • [1682]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1683]
    (a) the amino acid sequence of SEQ ID NO:94;
  • [1684]
    (b) a fragment of the amino acid sequence of SEQ ID NO:94, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; and
  • [1685]
    (c) the amino acid sequence encoded by the cDNA insert of clone bf15716 deposited under accession number ATCC 207088;
  • [1686]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:94. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 220 to amino acid 229 of SEQ ID NO:94.
  • [1687]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1688]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95;
  • [1689]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629;
  • [1690]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bk3432 deposited under accession number ATCC 207088;
  • [1691]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bk3432 deposited under accession number ATCC 207088;
  • [1692]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bk3432 deposited under accession number ATCC 207088;
  • [1693]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bk3432 deposited under accession number ATCC 207088;
  • [1694]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:96;
  • [1695]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:96;
  • [1696]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1697]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1698]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1699]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:95.
  • [1700]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629; the nucleotide sequence of the full-length protein coding sequence of clone bk3432 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone bk3432 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bk3432 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 63 to amino acid 72 of SEQ ID NO:96.
  • [1701]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:95.
  • [1702]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1703]
    (a) a process comprising the steps of:
  • [1704]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1705]
    (aa) SEQ ID NO:95, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:95; and
  • [1706]
    (ab) the nucleotide sequence of the cDNA insert of done bk3432 deposited under accession number ATCC 207088;
  • [1707]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1708]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1709]
    (b) a process comprising the steps of:
  • [1710]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1711]
    (ba) SEQ ID NO:95, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:95; and
  • [1712]
    (bb) the nucleotide sequence of the cDNA insert of clone bk3432 deposited under accession number ATCC 207088;
  • [1713]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1714]
    (iii) amplifying human DNA sequences; and
  • [1715]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1716]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:95 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:95, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:95. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629.
  • [1717]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1718]
    (a) the amino acid sequence of SEQ ID NO:96;
  • [1719]
    (b) a fragment of the amino acid sequence of SEQ ID NO:96, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; and
  • [1720]
    (c) the amino acid sequence encoded by the cDNA insert of clone bk3432 deposited under accession number ATCC 207088;
  • [1721]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:96. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 63 to amino acid 72 of SEQ ID NO:96.
  • [1722]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1723]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97;
  • [1724]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951;
  • [1725]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951;
  • [1726]
    (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295;
  • [1727]
    (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cd2052 deposited under accession number ATCC 207088;
  • [1728]
    (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cd2052 deposited under accession number ATCC 207088;
  • [1729]
    (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cd2052 deposited under accession number ATCC 207088;
  • [1730]
    (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cd2052 deposited under accession number ATCC 207088;
  • [1731]
    (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:98;
  • [1732]
    (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:98;
  • [1733]
    (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
  • [1734]
    (l) a polynucleotide which encodes a species homologue of the protein of (i) or 0) above;
  • [1735]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
  • [1736]
    (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:97.
  • [1737]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951; the nucleotide sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951; the nucleotide sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295; the nucleotide sequence of the full-length protein coding sequence of clone cd2052 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cd2052 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cd2052 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:98.
  • [1738]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:97.
  • [1739]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1740]
    (a) a process comprising the steps of:
  • [1741]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1742]
    (aa) SEQ ID NO:97, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:97; and
  • [1743]
    (ab) the nucleotide sequence of the cDNA insert of clone cd2052 deposited under accession number ATCC 207088;
  • [1744]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1745]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1746]
    (b) a process comprising the steps of:
  • [1747]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1748]
    (ba) SEQ ID NO:97, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:97; and
  • [1749]
    (bb) the nucleotide sequence of the cDNA insert of clone cd2052 deposited under accession number ATCC 207088;
  • [1750]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1751]
    (iii) amplifying human DNA sequences; and
  • [1752]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1753]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:97 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:97, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:97. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295.
  • [1754]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1755]
    (a) the amino acid sequence of SEQ ID NO:98;
  • [1756]
    (b) a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ID NO:98; and
  • [1757]
    (c) the amino acid sequence encoded by the cDNA insert of clone cd2052 deposited under accession number ATCC 207088;
  • [1758]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:98. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:98.
  • [1759]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1760]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99;
  • [1761]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443;
  • [1762]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443;
  • [1763]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cw12928 deposited under accession number ATCC 207088;
  • [1764]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cw12928 deposited under accession number ATCC 207088;
  • [1765]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cw12928 deposited under accession number ATCC 207088;
  • [1766]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cw12928 deposited under accession number ATCC 207088;
  • [1767]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:100;
  • [1768]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:100;
  • [1769]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [1770]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [1771]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [1772]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:99.
  • [1773]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443; the nucleotide sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443; the nucleotide sequence of the full-length protein coding sequence of clone cw12928 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cw12928 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cw12928 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:100, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:100.
  • [1774]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:99.
  • [1775]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1776]
    (a) a process comprising the steps of:
  • [1777]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1778]
    (aa) SEQ ID NO:99, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:99; and
  • [1779]
    (ab) the nucleotide sequence of the cDNA insert of clone cw12928 deposited under accession number ATCC 207088;
  • [1780]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1781]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1782]
    (b) a process comprising the steps of:
  • [1783]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1784]
    (ba) SEQ ID NO:99, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:99; and
  • [1785]
    (bb) the nucleotide sequence of the cDNA insert of clone cw12928 deposited under accession number ATCC 207088;
  • [1786]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1787]
    (iii) amplifying human DNA sequences; and
  • [1788]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1789]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:99 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:99, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:99. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443.
  • [1790]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1791]
    (a) the amino acid sequence of SEQ ID NO:100;
  • [1792]
    (b) a fragment of the amino acid sequence of SEQ ID NO:100, the fragment comprising eight contiguous amino acids of SEQ ID NO:100; and
  • [1793]
    (c) the amino acid sequence encoded by the cDNA insert of clone cw12928 deposited under accession number ATCC 207088;
  • [1794]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:100. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:100, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:100.
  • [1795]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1796]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101;
  • [1797]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447;
  • [1798]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cw14752 deposited under accession number ATCC 207088;
  • [1799]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cw14752 deposited under accession number ATCC 207088;
  • [1800]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cw14752 deposited under accession number ATCC 207088;
  • [1801]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cw14752 deposited under accession number ATCC 207088;
  • [1802]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:102;
  • [1803]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:102;
  • [1804]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1805]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1806]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1807]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:101.
  • [1808]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447; the nucleotide sequence of the full-length protein coding sequence of clone cw14752 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cw14752 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cw14752 deposited under accession number ATCC 207088.
  • [1809]
    In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:102, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:102.
  • [1810]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:101.
  • [1811]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1812]
    (a) a process comprising the steps of:
  • [1813]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1814]
    (aa) SEQ ID NO:101, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:101; and
  • [1815]
    (ab) the nucleotide sequence of the cDNA insert of clone cw14752 deposited under accession number ATCC 207088;
  • [1816]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1817]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1818]
    (b) a process comprising the steps of:
  • [1819]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1820]
    (ba) SEQ ID NO:101, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:101; and
  • [1821]
    (bb) the nucleotide sequence of the cDNA insert of clone cw14752 deposited under accession number ATCC 207088;
  • [1822]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1823]
    (iii) amplifying human DNA sequences; and
  • [1824]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1825]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:101 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:101, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447.
  • [1826]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1827]
    (a) the amino acid sequence of SEQ ID NO:102;
  • [1828]
    (b) a fragment of the amino acid sequence of SEQ ID NO:102, the fragment comprising eight contiguous amino acids of SEQ ID NO:102; and
  • [1829]
    (c) the amino acid sequence encoded by the cDNA insert of clone cw14752 deposited under accession number ATCC 207088;
  • [1830]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:102. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:102, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:102.
  • [1831]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1832]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103;
  • [1833]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954;
  • [1834]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd4284 deposited under accession number ATCC 207088;
  • [1835]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd4284 deposited under accession number ATCC 207088;
  • [1836]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd4284 deposited under accession number ATCC 207088;
  • [1837]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dd4284 deposited under accession number ATCC 207088;
  • [1838]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:104;
  • [1839]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:104;
  • [1840]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1841]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1842]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1843]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:103.
  • [1844]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954; the nucleotide sequence of the full-length protein coding sequence of clone dd4284 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dd4284 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dd4284 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 102 to amino acid 111 of SEQ ID NO:104.
  • [1845]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:103.
  • [1846]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1847]
    (a) a process comprising the steps of:
  • [1848]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1849]
    (aa) SEQ ID NO:103, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:103; and
  • [1850]
    (ab) the nucleotide sequence of the cDNA insert of clone dd4284 deposited under accession number ATCC 207088;
  • [1851]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1852]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1853]
    (b) a process comprising the steps of:
  • [1854]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1855]
    (ba) SEQ ID NO:103, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:103; and
  • [1856]
    (bb) the nucleotide sequence of the cDNA insert of clone dd4284 deposited under accession number ATCC 207088;
  • [1857]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1858]
    (iii) amplifying human DNA sequences; and
  • [1859]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1860]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:103 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:103, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:103. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954.
  • [1861]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1862]
    (a) the amino acid sequence of SEQ ID NO:104;
  • [1863]
    (b) a fragment of the amino acid sequence of SEQ ID NO:104, the fragment comprising eight contiguous amino acids of SEQ ID NO:104; and
  • [1864]
    (c) the amino acid sequence encoded by the cDNA insert of clone dd4284 deposited under accession number ATCC 207088;
  • [1865]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:104. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 102 to amino acid 111 of SEQ ID NO:104.
  • [1866]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1867]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105;
  • [1868]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895;
  • [1869]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dh107312 deposited under accession number ATCC 207088;
  • [1870]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dh107312 deposited under accession number ATCC 207088;
  • [1871]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dh107312 deposited under accession number ATCC 207088;
  • [1872]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dh107312 deposited under accession number ATCC 207088;
  • [1873]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:106;
  • [1874]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:106;
  • [1875]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1876]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1877]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1878]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:105.
  • [1879]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895; the nucleotide sequence of the full-length protein coding sequence of clone dh107312 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dh107312 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dh107312 deposited under accession number ATCC 207088.
  • [1880]
    In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:106.
  • [1881]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:105.
  • [1882]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1883]
    (a) a process comprising the steps of:
  • [1884]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1885]
    (aa) SEQ ID NO:105, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:105; and
  • [1886]
    (ab) the nucleotide sequence of the cDNA insert of clone dh107312 deposited under accession number ATCC 207088;
  • [1887]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1888]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1889]
    (b) a process comprising the steps of:
  • [1890]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1891]
    (ba) SEQ ID NO:105, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:105; and
  • [1892]
    (bb) the nucleotide sequence of the cDNA insert of clone dh107312 deposited under accession number ATCC 207088;
  • [1893]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1894]
    (iii) amplifying human DNA sequences; and
  • [1895]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1896]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:105 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:105, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895.
  • [1897]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1898]
    (a) the amino acid sequence of SEQ ID NO:106;
  • [1899]
    (b) a fragment of the amino acid sequence of SEQ ID NO:106, the fragment comprising eight contiguous amino acids of SEQ ID NO:106; and
  • [1900]
    (c) the amino acid sequence encoded by the cDNA insert of clone dh107312 deposited under accession number ATCC 207088;
  • [1901]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:106. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:106.
  • [1902]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1903]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:107;
  • [1904]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791;
  • [1905]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dw781 deposited under accession number ATCC 207088;
  • [1906]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dw781 deposited under accession number ATCC 207088;
  • [1907]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dw781 deposited under accession number ATCC 207088;
  • [1908]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dw781 deposited under accession number ATCC 207088;
  • [1909]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:108;
  • [1910]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:108;
  • [1911]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1912]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1913]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1914]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:107.
  • [1915]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791; the nucleotide sequence of the full-length protein coding sequence of clone dw781 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dw781 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dw781 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:108, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:108.
  • [1916]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:107.
  • [1917]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1918]
    (a) a process comprising the steps of:
  • [1919]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1920]
    (aa) SEQ ID NO:107, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:107; and
  • [1921]
    (ab) the nucleotide sequence of the cDNA insert of clone dw781 deposited under accession number ATCC 207088;
  • [1922]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1923]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1924]
    (b) a process comprising the steps of:
  • [1925]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1926]
    (ba) SEQ ID NO:107, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:107; and
  • [1927]
    (bb) the nucleotide sequence of the cDNA insert of clone dw781 deposited under accession number ATCC 207088;
  • [1928]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1929]
    (iii) amplifying human DNA sequences; and
  • [1930]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1931]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:107 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:107, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:107. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791.
  • [1932]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1933]
    (a) the amino acid sequence of SEQ ID NO:108;
  • [1934]
    (b) a fragment of the amino acid sequence of SEQ ID NO:108, the fragment comprising eight contiguous amino acids of SEQ ID NO:108; and
  • [1935]
    (c) the amino acid sequence encoded by the cDNA insert of clone dw781 deposited under accession number ATCC 207088;
  • [1936]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:108. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:108, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:108.
  • [1937]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1938]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:109;
  • [1939]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944;
  • [1940]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fh11611 deposited under accession number ATCC 207088;
  • [1941]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fh11611 deposited under accession number ATCC 207088;
  • [1942]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fh11611 deposited under accession number ATCC 207088;
  • [1943]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fh11611 deposited under accession number ATCC 207088;
  • [1944]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:110;
  • [1945]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:110;
  • [1946]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1947]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1948]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1949]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:109.
  • [1950]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944; the nucleotide sequence of the full-length protein coding sequence of clone fh11611 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone fh11611 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fh11611 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:110, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising the amino acid sequence from amino acid 136 to amino acid 145 of SEQ ID NO:110.
  • [1951]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:109.
  • [1952]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1953]
    (a) a process comprising the steps of:
  • [1954]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1955]
    (aa) SEQ ID NO:109, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:109; and
  • [1956]
    (ab) the nucleotide sequence of the cDNA insert of clone fh11611 deposited under accession number ATCC 207088;
  • [1957]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1958]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1959]
    (b) a process comprising the steps of:
  • [1960]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1961]
    (ba) SEQ ID NO:109, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:109; and
  • [1962]
    (bb) the nucleotide sequence of the cDNA insert of clone fh11611 deposited under accession number ATCC 207088;
  • [1963]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1964]
    (iii) amplifying human DNA sequences; and
  • [1965]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [1966]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:109 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:109, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:109. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944.
  • [1967]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [1968]
    (a) the amino acid sequence of SEQ ID NO:110;
  • [1969]
    (b) a fragment of the amino acid sequence of SEQ ID NO:110, the fragment comprising eight contiguous amino acids of SEQ ID NO:110; and
  • [1970]
    (c) the amino acid sequence encoded by the cDNA insert of clone fh11611 deposited under accession number ATCC 207088;
  • [1971]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:110. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:110, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising the amino acid sequence from amino acid 136 to amino acid 145 of SEQ ID NO:110.
  • [1972]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [1973]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111;
  • [1974]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610;
  • [1975]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fy35614 deposited under accession number ATCC 207088;
  • [1976]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fy35614 deposited under accession number ATCC 207088;
  • [1977]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fy35614 deposited under accession number ATCC 207088;
  • [1978]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fy35614 deposited under accession number ATCC 207088;
  • [1979]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:112;
  • [1980]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:112;
  • [1981]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [1982]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [1983]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [1984]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:111.
  • [1985]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610; the nucleotide sequence of the full-length protein coding sequence of clone fy35614 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone fy35614 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fy35614 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:112.
  • [1986]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:111.
  • [1987]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [1988]
    (a) a process comprising the steps of:
  • [1989]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1990]
    (aa) SEQ ID NO:111, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:111; and
  • [1991]
    (ab) the nucleotide sequence of the cDNA insert of clone fy35614 deposited under accession number ATCC 207088;
  • [1992]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [1993]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [1994]
    (b) a process comprising the steps of:
  • [1995]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [1996]
    (ba) SEQ ID NO:111, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:111; and
  • [1997]
    (bb) the nucleotide sequence of the cDNA insert of clone fy35614 deposited under accession number ATCC 207088;
  • [1998]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [1999]
    (iii) amplifying human DNA sequences; and
  • [2000]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2001]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:111 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:111, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:111. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610.
  • [2002]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2003]
    (a) the amino acid sequence of SEQ ID NO:112;
  • [2004]
    (b) a fragment of the amino acid sequence of SEQ ID NO:112, the fragment comprising eight contiguous amino acids of SEQ ID NO:112; and
  • [2005]
    (c) the amino acid sequence encoded by the cDNA insert of clone fy35614 deposited under accession number ATCC 207088;
  • [2006]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:112. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:112.
  • [2007]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2008]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113;
  • [2009]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669;
  • [2010]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669;
  • [2011]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone iw661 deposited under accession number ATCC 207088;
  • [2012]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone iw661 deposited under accession number ATCC 207088;
  • [2013]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone iw661 deposited under accession number ATCC 207088;
  • [2014]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone iw661 deposited under accession number ATCC 207088;
  • [2015]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:114;
  • [2016]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:114;
  • [2017]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2018]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2019]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2020]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:113.
  • [2021]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669; the nucleotide sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669; the nucleotide sequence of the full-length protein coding sequence of clone iw661 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone iw661 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone iw661 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:114, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:114.
  • [2022]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:113.
  • [2023]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2024]
    (a) a process comprising the steps of:
  • [2025]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2026]
    (aa) SEQ ID NO:113, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:113; and
  • [2027]
    (ab) the nucleotide sequence of the cDNA insert of clone iw661 deposited under accession number ATCC 207088;
  • [2028]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2029]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2030]
    (b) a process comprising the steps of:
  • [2031]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2032]
    (ba) SEQ ID NO:113, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:113; and
  • [2033]
    (bb) the nucleotide sequence of the cDNA insert of clone iw661 deposited under accession number ATCC 207088;
  • [2034]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2035]
    (iii) amplifying human DNA sequences; and
  • [2036]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2037]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:113 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:113, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:113. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669.
  • [2038]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2039]
    (a) the amino acid sequence of SEQ ID NO:114;
  • [2040]
    (b) a fragment of the amino acid sequence of SEQ ID NO:114, the fragment comprising eight contiguous amino acids of SEQ ID NO:114; and
  • [2041]
    (c) the amino acid sequence encoded by the cDNA insert of clone iw661 deposited under accession number ATCC 207088;
  • [2042]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:114. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:114, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:114.
  • [2043]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2044]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:115;
  • [2045]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416;
  • [2046]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone kh134 deposited under accession number ATCC 207089;
  • [2047]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone kh134 deposited under accession number ATCC 207089;
  • [2048]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone kh134 deposited under accession number ATCC 207089;
  • [2049]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone kh134 deposited under accession number ATCC 207089;
  • [2050]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:116;
  • [2051]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:116;
  • [2052]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2053]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2054]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2055]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:115.
  • [2056]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416; the nucleotide sequence of the full-length protein coding sequence of clone kh134 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone kh134 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone kh134 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:116, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:116.
  • [2057]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:115.
  • [2058]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2059]
    (a) a process comprising the steps of:
  • [2060]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2061]
    (aa) SEQ ID NO:115, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:115; and
  • [2062]
    (ab) the nucleotide sequence of the cDNA insert of clone kh134 deposited under accession number ATCC 207089;
  • [2063]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2064]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2065]
    (b) a process comprising the steps of:
  • [2066]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2067]
    (ba) SEQ ID NO:115, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:115; and
  • [2068]
    (bb) the nucleotide sequence of the cDNA insert of clone kh134 deposited under accession number ATCC 207089;
  • [2069]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2070]
    (iii) amplifying human DNA sequences; and
  • [2071]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2072]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:115, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:115 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:115, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:115. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416.
  • [2073]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2074]
    (a) the amino acid sequence of SEQ ID NO:116;
  • [2075]
    (b) a fragment of the amino acid sequence of SEQ ID NO:116, the fragment comprising eight contiguous amino acids of SEQ ID NO:116; and
  • [2076]
    (c) the amino acid sequence encoded by the cDNA insert of clone kh134 deposited under accession number ATCC 207089;
  • [2077]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:116. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:116, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:116.
  • [2078]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2079]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:117;
  • [2080]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602;
  • [2081]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ko2584 deposited under accession number ATCC 207089;
  • [2082]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ko2584 deposited under accession number ATCC 207089;
  • [2083]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ko2584 deposited under accession number ATCC 207089;
  • [2084]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ko2584 deposited under accession number ATCC 207089;
  • [2085]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:118;
  • [2086]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:118;
  • [2087]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2088]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2089]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2090]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:117.
  • [2091]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602; the nucleotide sequence of the full-length protein coding sequence of clone ko2584 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone ko2584 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ko2584 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:118, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:118.
  • [2092]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:117.
  • [2093]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2094]
    (a) a process comprising the steps of:
  • [2095]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2096]
    (aa) SEQ ID NO:117, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:117; and
  • [2097]
    (ab) the nucleotide sequence of the cDNA insert of clone ko2584 deposited under accession number ATCC 207089;
  • [2098]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2099]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2100]
    (b) a process comprising the steps of:
  • [2101]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2102]
    (ba) SEQ ID NO:117, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:117; and
  • [2103]
    (bb) the nucleotide sequence of the cDNA insert of clone ko2584 deposited under accession number ATCC 207089;
  • [2104]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2105]
    (iii) amplifying human DNA sequences; and
  • [2106]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2107]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:117, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:117 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:117, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:117. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602.
  • [2108]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2109]
    (a) the amino acid sequence of SEQ ID NO:118;
  • [2110]
    (b) a fragment of the amino acid sequence of SEQ ID NO:118, the fragment comprising eight contiguous amino acids of SEQ ID NO:118; and
  • [2111]
    (c) the amino acid sequence encoded by the cDNA insert of clone ko2584 deposited under accession number ATCC 207089;
  • [2112]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:118. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:118, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:118.
  • [2113]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2114]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119;
  • [2115]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739;
  • [2116]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone kv108 deposited under accession number ATCC 207089;
  • [2117]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone kv108 deposited under accession number ATCC 207089;
  • [2118]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ky108 deposited under accession number ATCC 207089;
  • [2119]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ky108 deposited under accession number ATCC 207089;
  • [2120]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:120;
  • [2121]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:120;
  • [2122]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2123]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2124]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2125]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:119.
  • [2126]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739; the nucleotide sequence of the full-length protein coding sequence of clone kv108 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone kv108 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ky108 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:120.
  • [2127]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:119.
  • [2128]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2129]
    (a) a process comprising the steps of:
  • [2130]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2131]
    (aa) SEQ ID NO:119, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:119; and
  • [2132]
    (ab) the nucleotide sequence of the cDNA insert of clone kv108 deposited under accession number ATCC 207089;
  • [2133]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2134]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2135]
    (b) a process comprising the steps of:
  • [2136]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2137]
    (ba) SEQ ID NO:119, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:119; and
  • [2138]
    (bb) the nucleotide sequence of the cDNA insert of clone ky108 deposited under accession number ATCC 207089;
  • [2139]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2140]
    (iii) amplifying human DNA sequences; and
  • [2141]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2142]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:119 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:119, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:119. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739.
  • [2143]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2144]
    (a) the amino acid sequence of SEQ ID NO:120;
  • [2145]
    (b) a fragment of the amino acid sequence of SEQ ID NO:120, the fragment comprising eight contiguous amino acids of SEQ ID NO:120; and
  • [2146]
    (c) the amino acid sequence encoded by the cDNA insert of clone ky108 deposited under accession number ATCC 207089;
  • [2147]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:120. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:120.
  • [2148]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2149]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121;
  • [2150]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310;
  • [2151]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone LL893 deposited under accession number ATCC 207089;
  • [2152]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone LL893 deposited under accession number ATCC 207089;
  • [2153]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone LL893 deposited under accession number ATCC 207089;
  • [2154]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone LL893 deposited under accession number ATCC 207089;
  • [2155]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:122;
  • [2156]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:122;
  • [2157]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2158]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2159]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2160]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:121.
  • [2161]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310; the nucleotide sequence of the full-length protein coding sequence of clone LL893 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone LL893 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone LL893 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty contiguous amino acids of SEQ ID NO:122, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:122.
  • [2162]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:121.
  • [2163]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2164]
    (a) a process comprising the steps of:
  • [2165]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2166]
    (aa) SEQ ID NO:121, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:121; and
  • [2167]
    (ab) the nucleotide sequence of the cDNA insert of clone LL893 deposited under accession number ATCC 207089;
  • [2168]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2169]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2170]
    (b) a process comprising the steps of:
  • [2171]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2172]
    (ba) SEQ ID NO:121, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:121; and
  • [2173]
    (bb) the nucleotide sequence of the cDNA insert of clone LL893 deposited under accession number ATCC 207089;
  • [2174]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2175]
    (iii) amplifying human DNA sequences; and
  • [2176]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2177]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:121, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:121 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:121, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:121. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310.
  • [2178]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2179]
    (a) the amino acid sequence of SEQ ID NO:122;
  • [2180]
    (b) a fragment of the amino acid sequence of SEQ ID NO:122, the fragment comprising eight contiguous amino acids of SEQ ID NO:122; and
  • [2181]
    (c) the amino acid sequence encoded by the cDNA insert of clone LL893 deposited under accession number ATCC 207089;
  • [2182]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:122. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:122, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:122.
  • [2183]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2184]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123;
  • [2185]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288;
  • [2186]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mc3001 deposited under accession number ATCC 207089;
  • [2187]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mc3001 deposited under accession number ATCC 207089;
  • [2188]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mc3001 deposited under accession number ATCC 207089;
  • [2189]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mc3001 deposited under accession number ATCC 207089;
  • [2190]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:124;
  • [2191]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:124;
  • [2192]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2193]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2194]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2195]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:123.
  • [2196]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288; the nucleotide sequence of the full-length protein coding sequence of clone mc3001 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mc3001 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mc3001 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:124.
  • [2197]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:123.
  • [2198]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2199]
    (a) a process comprising the steps of:
  • [2200]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2201]
    (aa) SEQ ID NO:123, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:123; and
  • [2202]
    (ab) the nucleotide sequence of the cDNA insert of clone mc3001 deposited under accession number ATCC 207089;
  • [2203]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2204]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2205]
    (b) a process comprising the steps of:
  • [2206]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2207]
    (ba) SEQ ID NO:123, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:123; and
  • [2208]
    (bb) the nucleotide sequence of the cDNA insert of clone mc3001 deposited under accession number ATCC 207089;
  • [2209]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2210]
    (iii) amplifying human DNA sequences; and
  • [2211]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2212]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:123 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:123, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:123. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288.
  • [2213]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2214]
    (a) the amino acid sequence of SEQ ID NO:124;
  • [2215]
    (b) a fragment of the amino acid sequence of SEQ ID NO:124, the fragment comprising eight contiguous amino acids of SEQ ID NO:124; and
  • [2216]
    (c) the amino acid sequence encoded by the cDNA insert of clone mc3001 deposited under accession number ATCC 207089;
  • [2217]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:124. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:124.
  • [2218]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2219]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125;
  • [2220]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449;
  • [2221]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ml2271 deposited under accession number ATCC 207089;
  • [2222]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ml2271 deposited under accession number ATCC 207089;
  • [2223]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ml2271 deposited under accession number ATCC 207089;
  • [2224]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ml2271 deposited under accession number ATCC 207089;
  • [2225]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:126;
  • [2226]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:126;
  • [2227]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2228]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2229]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2230]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:125.
  • [2231]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449; the nucleotide sequence of the full-length protein coding sequence of clone ml2271 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone ml2271 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ml2271 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:126, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 370 to amino acid 379 of SEQ ID NO:126.
  • [2232]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:125.
  • [2233]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2234]
    (a) a process comprising the steps of:
  • [2235]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2236]
    (aa) SEQ ID NO:125, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:125; and
  • [2237]
    (ab) the nucleotide sequence of the cDNA insert of clone ml2271 deposited under accession number ATCC 207089;
  • [2238]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2239]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2240]
    (b) a process comprising the steps of:
  • [2241]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2242]
    (ba) SEQ ID NO:125, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:125; and
  • [2243]
    (bb) the nucleotide sequence of the cDNA insert of clone ml2271 deposited under accession number ATCC 207089;
  • [2244]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2245]
    (iii) amplifying human DNA sequences; and
  • [2246]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2247]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:125 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:125, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:125. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449.
  • [2248]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2249]
    (a) the amino acid sequence of SEQ ID NO:126;
  • [2250]
    (b) a fragment of the amino acid sequence of SEQ ID NO:126, the fragment comprising eight contiguous amino acids of SEQ ID NO:126; and
  • [2251]
    (c) the amino acid sequence encoded by the cDNA insert of clone ml2271 deposited under accession number ATCC 207089;
  • [2252]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:126. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:126, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 370 to amino acid 379 of SEQ ID NO:126.
  • [2253]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2254]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127;
  • [2255]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980;
  • [2256]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mm3676 deposited under accession number ATCC 207089;
  • [2257]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mm3676 deposited under accession number ATCC 207089;
  • [2258]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mm3676 deposited under accession number ATCC 207089;
  • [2259]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mm3676 deposited under accession number ATCC 207089;
  • [2260]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:128;
  • [2261]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:128;
  • [2262]
    (i) a polynucleotide which is an aelic variant of a polynucleotide of (a)-(f) above;
  • [2263]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2264]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2265]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:127.
  • [2266]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980; the nucleotide sequence of the full-length protein coding sequence of clone mm3676 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mm3676 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mm3676 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 311 to amino acid 320 of SEQ ID NO:128.
  • [2267]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:127.
  • [2268]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2269]
    (a) a process comprising the steps of:
  • [2270]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2271]
    (aa) SEQ ID NO:127, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:127; and
  • [2272]
    (ab) the nucleotide sequence of the cDNA insert of clone mm3676 deposited under accession number ATCC 207089;
  • [2273]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2274]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2275]
    (b) a process comprising the steps of:
  • [2276]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2277]
    (ba) SEQ ID NO:127, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:127; and
  • [2278]
    (bb) the nucleotide sequence of the cDNA insert of clone mm3676 deposited under accession number ATCC 207089;
  • [2279]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2280]
    (iii) amplifying human DNA sequences; and
  • [2281]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2282]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:127 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:127, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:127. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980.
  • [2283]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2284]
    (a) the amino acid sequence of SEQ ID NO:128;
  • [2285]
    (b) a fragment of the amino acid sequence of SEQ ID NO:128, the fragment comprising eight contiguous amino acids of SEQ ID NO:128; and
  • [2286]
    (c) the amino acid sequence encoded by the cDNA insert of clone mm3676 deposited under accession number ATCC 207089;
  • [2287]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:128. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 311 to amino acid 320 of SEQ ID NO:128.
  • [2288]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2289]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129;
  • [2290]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856;
  • [2291]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mt1243 deposited under accession number ATCC 207089;
  • [2292]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mt1243 deposited under accession number ATCC 207089;
  • [2293]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mt1243 deposited under accession number ATCC 207089;
  • [2294]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mt1243 deposited under accession number ATCC 207089;
  • [2295]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:130;
  • [2296]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:130;
  • [2297]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2298]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2299]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2300]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:129.
  • [2301]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856; the nucleotide sequence of the full-length protein coding sequence of clone mt1243 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mt1243 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mt1243 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:130, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:130.
  • [2302]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:129.
  • [2303]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2304]
    (a) a process comprising the steps of:
  • [2305]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2306]
    (aa) SEQ ID NO:129, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:129; and
  • [2307]
    (ab) the nucleotide sequence of the cDNA insert of clone mt1243 deposited under accession number ATCC 207089;
  • [2308]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2309]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2310]
    (b) a process comprising the steps of:
  • [2311]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2312]
    (ba) SEQ ID NO:129, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:129; and
  • [2313]
    (bb) the nucleotide sequence of the cDNA insert of clone mt1243 deposited under accession number ATCC 207089;
  • [2314]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2315]
    (iii) amplifying human DNA sequences; and
  • [2316]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2317]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:129 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:129, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:129. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856.
  • [2318]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2319]
    (a) the amino acid sequence of SEQ ID NO:130;
  • [2320]
    (b) a fragment of the amino acid sequence of SEQ ID NO:130, the fragment comprising eight contiguous amino acids of SEQ ID NO:130; and
  • [2321]
    (c) the amino acid sequence encoded by the cDNA insert of clone mt1243 deposited under accession number ATCC 207089;
  • [2322]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:130. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:130, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:130.
  • [2323]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2324]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131;
  • [2325]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940;
  • [2326]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940;
  • [2327]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nf563 deposited under accession number ATCC 207089;
  • [2328]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nf563 deposited under accession number ATCC 207089;
  • [2329]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nf563 deposited under accession number ATCC 207089;
  • [2330]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nf563 deposited under accession number ATCC 207089;
  • [2331]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:132;
  • [2332]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:132;
  • [2333]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2334]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2335]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2336]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:131.
  • [2337]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940; the nucleotide sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940; the nucleotide sequence of the full-length protein coding sequence of clone nf563 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone nf563 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nf563 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 342 to amino acid 351 of SEQ ID NO:132.
  • [2338]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:131.
  • [2339]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2340]
    (a) a process comprising the steps of:
  • [2341]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2342]
    (aa) SEQ ID NO:131, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:131; and
  • [2343]
    (ab) the nucleotide sequence of the cDNA insert of clone nf563 deposited under accession number ATCC 207089;
  • [2344]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2345]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2346]
    (b) a process comprising the steps of:
  • [2347]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2348]
    (ba) SEQ ID NO:131, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:131; and
  • [2349]
    (bb) the nucleotide sequence of the cDNA insert of clone nf563 deposited under accession number ATCC 207089;
  • [2350]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2351]
    (iii) amplifying human DNA sequences; and
  • [2352]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2353]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:131 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:131, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:131. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940.
  • [2354]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2355]
    (a) the amino acid sequence of SEQ ID NO:132;
  • [2356]
    (b) a fragment of the amino acid sequence of SEQ ID NO:132, the fragment comprising eight contiguous amino acids of SEQ ID NO:132; and
  • [2357]
    (c) the amino acid sequence encoded by the cDNA insert of clone nf563 deposited under accession number ATCC 207089;
  • [2358]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:132. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 342 to amino acid 351 of SEQ ID NO:132.
  • [2359]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2360]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133;
  • [2361]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448;
  • [2362]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448;
  • [2363]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qy4422 deposited under accession number ATCC 207089;
  • [2364]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy442 2 deposited under accession number ATCC 207089;
  • [2365]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qy4422 deposited under accession number ATCC 207089;
  • [2366]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qy4422 deposited under accession number ATCC 207089;
  • [2367]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:134;
  • [2368]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:134;
  • [2369]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2370]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2371]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2372]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:133.
  • [2373]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448; the nucleotide sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448; the nucleotide sequence of the full-length protein coding sequence of clone qy4422 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone qy4422 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy4422 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:134.
  • [2374]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:133.
  • [2375]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2376]
    (a) a process comprising the steps of:
  • [2377]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2378]
    (aa) SEQ ID NO:133, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:133; and
  • [2379]
    (ab) the nucleotide sequence of the cDNA insert of clone qy4422 deposited under accession number ATCC 207089;
  • [2380]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2381]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2382]
    (b) a process comprising the steps of:
  • [2383]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2384]
    (ba) SEQ ID NO:133, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:133; and
  • [2385]
    (bb) the nucleotide sequence of the cDNA insert of clone qy4422 deposited under accession number ATCC 207089;
  • [2386]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2387]
    (iii) amplifying human DNA sequences; and
  • [2388]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2389]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:133 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:133, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:133. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448.
  • [2390]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2391]
    (a) the amino acid sequence of SEQ ID NO:134;
  • [2392]
    (b) a fragment of the amino acid sequence of SEQ ID NO:134, the fragment comprising eight contiguous amino acids of SEQ ID NO:134; and
  • [2393]
    (c) the amino acid sequence encoded by the cDNA insert of clone qy4422 deposited under accession number ATCC 207089;
  • [2394]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:134. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:134.
  • [2395]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2396]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135;
  • [2397]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777;
  • [2398]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777;
  • [2399]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rj21414 deposited under accession number ATCC 207089;
  • [2400]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rj21414 deposited under accession number ATCC 207089;
  • [2401]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rj21414 deposited under accession number ATCC 207089;
  • [2402]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rj21414 deposited under accession number ATCC 207089;
  • [2403]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:136;
  • [2404]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:136;
  • [2405]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2406]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2407]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2408]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:135.
  • [2409]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777; the nucleotide sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777; the nucleotide sequence of the full-length protein coding sequence of clone rj21414 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone rj21414 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rj21414 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:136, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:136.
  • [2410]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:135.
  • [2411]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2412]
    (a) a process comprising the steps of:
  • [2413]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2414]
    (aa) SEQ ID NO:135, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:135; and
  • [2415]
    (ab) the nucleotide sequence of the cDNA insert of clone rj21414 deposited under accession number ATCC 207089;
  • [2416]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2417]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2418]
    (b) a process comprising the steps of:
  • [2419]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2420]
    (ba) SEQ ID NO:135, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:135; and
  • [2421]
    (bb) the nucleotide sequence of the cDNA insert of clone rj21414 deposited under accession number ATCC 207089;
  • [2422]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2423]
    (iii) amplifying human DNA sequences; and
  • [2424]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2425]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:135 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:135, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:135. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777.
  • [2426]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2427]
    (a) the amino acid sequence of SEQ ID NO:136;
  • [2428]
    (b) a fragment of the amino acid sequence of SEQ ID NO:136, the fragment comprising eight contiguous amino acids of SEQ ID NO:136; and
  • [2429]
    (c) the amino acid sequence encoded by the cDNA insert of clone rj21414 deposited under accession number ATCC 207089;
  • [2430]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:136. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:136, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:136.
  • [2431]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2432]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137;
  • [2433]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745;
  • [2434]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745;
  • [2435]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of done rk803 deposited under accession number ATCC 207089;
  • [2436]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rk803 deposited under accession number ATCC 207089;
  • [2437]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rk803 deposited under accession number ATCC 207089;
  • [2438]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rk803 deposited under accession number ATCC 207089;
  • [2439]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:138;
  • [2440]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:138;
  • [2441]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2442]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2443]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2444]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:137.
  • [2445]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745; the nucleotide sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745; the nucleotide sequence of the full-length protein coding sequence of clone rk803 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone rk803 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rk803 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:138, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:138.
  • [2446]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:137.
  • [2447]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2448]
    (a) a process comprising the steps of:
  • [2449]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2450]
    (aa) SEQ ID NO:137, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:137; and
  • [2451]
    (ab) the nucleotide sequence of the cDNA insert of clone rk803 deposited under accession number ATCC 207089;
  • [2452]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2453]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2454]
    (b) a process comprising the steps of:
  • [2455]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2456]
    (ba) SEQ ID NO:137, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:137; and
  • [2457]
    (bb) the nucleotide sequence of the cDNA insert of clone rk803 deposited under accession number ATCC 207089;
  • [2458]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2459]
    (iii) amplifying human DNA sequences; and
  • [2460]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2461]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:137 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:137, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:137. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745.
  • [2462]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2463]
    (a) the amino acid sequence of SEQ ID NO:138;
  • [2464]
    (b) a fragment of the amino acid sequence of SEQ ID NO:138, the fragment comprising eight contiguous amino acids of SEQ ID NO:138; and
  • [2465]
    (c) the amino acid sequence encoded by the cDNA insert of clone rk803 deposited under accession number ATCC 207089;
  • [2466]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:138. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:138, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:138.
  • [2467]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2468]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:139;
  • [2469]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274;
  • [2470]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone au3642 deposited under accession number ATCC 207187;
  • [2471]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone au3642 deposited under accession number ATCC 207187;
  • [2472]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone au3642 deposited under accession number ATCC 207187;
  • [2473]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone au3642 deposited under accession number ATCC 207187;
  • [2474]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:140;
  • [2475]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:140;
  • [2476]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2477]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2478]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2479]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:139.
  • [2480]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274; the nucleotide sequence of the full-length protein coding sequence of clone au3642 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone au3642 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone au3642 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:140, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:140.
  • [2481]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:139.
  • [2482]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2483]
    (a) a process comprising the steps of:
  • [2484]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2485]
    (aa) SEQ ID NO:139, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:139; and
  • [2486]
    (ab) the nucleotide sequence of the cDNA insert of done au3642 deposited under accession number ATCC 207187;
  • [2487]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2488]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2489]
    (b) a process comprising the steps of:
  • [2490]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2491]
    (ba) SEQ ID NO:139, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:139; and
  • [2492]
    (bb) the nucleotide sequence of the cDNA insert of clone au3642 deposited under accession number ATCC 207187;
  • [2493]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2494]
    (iii) amplifying human DNA sequences; and
  • [2495]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2496]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:139 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:139, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:139. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274.
  • [2497]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2498]
    (a) the amino acid sequence of SEQ ID NO:140;
  • [2499]
    (b) a fragment of the amino acid sequence of SEQ ID NO:140, the fragment comprising eight contiguous amino acids of SEQ ID NO:140; and
  • [2500]
    (c) the amino acid sequence encoded by the cDNA insert of clone au3642 deposited under accession number ATCC 207187;
  • [2501]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:140. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:140, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:140.
  • [2502]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2503]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:141;
  • [2504]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774;
  • [2505]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bo54913 deposited under accession number ATCC 207187;
  • [2506]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bo54913 deposited under accession number ATCC 207187;
  • [2507]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bo54913 deposited under accession number ATCC 207187;
  • [2508]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bo54913 deposited under accession number ATCC 207187;
  • [2509]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:142;
  • [2510]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:142;
  • [2511]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2512]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2513]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2514]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:141.
  • [2515]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774; the nucleotide sequence of the full-length protein coding sequence of clone bo54913 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone bo54913 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bo54913 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:142, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:142.
  • [2516]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:141.
  • [2517]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2518]
    (a) a process comprising the steps of:
  • [2519]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2520]
    (aa) SEQ ID NO:141, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:141; and
  • [2521]
    (ab) the nucleotide sequence of the cDNA insert of clone bo54913 deposited under accession number ATCC 207187;
  • [2522]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2523]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2524]
    (b) a process comprising the steps of:
  • [2525]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2526]
    (ba) SEQ ID NO:141, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:141; and
  • [2527]
    (bb) the nucleotide sequence of the cDNA insert of clone bo54913 deposited under accession number ATCC 207187;
  • [2528]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2529]
    (iii) amplifying human DNA sequences; and
  • [2530]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2531]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:141 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:141, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:141. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774.
  • [2532]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2533]
    (a) the amino acid sequence of SEQ ID NO:142;
  • [2534]
    (b) a fragment of the amino acid sequence of SEQ ID NO:142, the fragment comprising eight contiguous amino acids of SEQ ID NO:142; and
  • [2535]
    (c) the amino acid sequence encoded by the cDNA insert of clone bo54913 deposited under accession number ATCC 207187;
  • [2536]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:142. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:142, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:142.
  • [2537]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2538]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143;
  • [2539]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969;
  • [2540]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969;
  • [2541]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone da5293 deposited under accession number ATCC 207187;
  • [2542]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone da5293 deposited under accession number ATCC 207187;
  • [2543]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone da5293 deposited under accession number ATCC 207187;
  • [2544]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone da5293 deposited under accession number ATCC 207187;
  • [2545]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:144;
  • [2546]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:144;
  • [2547]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2548]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2549]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2550]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:143.
  • [2551]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969; the nucleotide sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969; the nucleotide sequence of the full-length protein coding sequence of clone da5293 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone da5293 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone da5293 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:144, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:144.
  • [2552]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:143.
  • [2553]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2554]
    (a) a process comprising the steps of:
  • [2555]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2556]
    (aa) SEQ ID NO:143, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:143; and
  • [2557]
    (ab) the nucleotide sequence of the cDNA insert of clone da5293 deposited under accession number ATCC 207187;
  • [2558]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2559]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2560]
    (b) a process comprising the steps of:
  • [2561]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2562]
    (ba) SEQ ID NO:143, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:143; and
  • [2563]
    (bb) the nucleotide sequence of the cDNA insert of clone da5293 deposited under accession number ATCC 207187;
  • [2564]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2565]
    (iii) amplifying human DNA sequences; and
  • [2566]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2567]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:143 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:143, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:143. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969.
  • [2568]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2569]
    (a) the amino acid sequence of SEQ ID NO:144;
  • [2570]
    (b) a fragment of the amino acid sequence of SEQ ID NO:144, the fragment comprising eight contiguous amino acids of SEQ ID NO:144; and
  • [2571]
    (c) the amino acid sequence encoded by the cDNA insert of clone da5293 deposited under accession number ATCC 207187;
  • [2572]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:144. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:144, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:144.
  • [2573]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2574]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145;
  • [2575]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667;
  • [2576]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667;
  • [2577]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dm3653 deposited under accession number ATCC 207187;
  • [2578]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dm3653 deposited under accession number ATCC 207187;
  • [2579]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dm3653 deposited under accession number ATCC 207187;
  • [2580]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dm3653 deposited under accession number ATCC 207187;
  • [2581]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:146;
  • [2582]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:146;
  • [2583]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2584]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2585]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2586]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:145.
  • [2587]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667; the nucleotide sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667; the nucleotide sequence of the full-length protein coding sequence of clone dm3653 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone dm3653 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dm3653 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:146, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:146.
  • [2588]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:145.
  • [2589]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2590]
    (a) a process comprising the steps of:
  • [2591]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2592]
    (aa) SEQ ID NO:145, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:145; and
  • [2593]
    (ab) the nucleotide sequence of the cDNA insert of clone dm3653 deposited under accession number ATCC 207187;
  • [2594]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2595]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2596]
    (b) a process comprising the steps of:
  • [2597]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2598]
    (ba) SEQ ID NO:145, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:145; and
  • [2599]
    (bb) the nucleotide sequence of the cDNA insert of clone dm3653 deposited under accession number ATCC 207187;
  • [2600]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2601]
    (iii) amplifying human DNA sequences; and
  • [2602]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2603]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:145 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:145, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:145. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667.
  • [2604]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2605]
    (a) the amino acid sequence of SEQ ID NO:146;
  • [2606]
    (b) a fragment of the amino acid sequence of SEQ ID NO:146, the fragment comprising eight contiguous amino acids of SEQ ID NO:146; and
  • [2607]
    (c) the amino acid sequence encoded by the cDNA insert of clone dm3653 deposited under accession number ATCC 207187;
  • [2608]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:146. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:146, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:146.
  • [2609]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2610]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:147;
  • [2611]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368;
  • [2612]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fa1711 deposited under accession number ATCC 207187;
  • [2613]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fa1711 deposited under accession number ATCC 207187;
  • [2614]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fa1711 deposited under accession number ATCC 207187;
  • [2615]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fa1711 deposited under accession number ATCC 207187;
  • [2616]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:148;
  • [2617]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:148;
  • [2618]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2619]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2620]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2621]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:147.
  • [2622]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368; the nucleotide sequence of the full-length protein coding sequence of clone fa1711 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone fa1711 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fa1711 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:148, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:148.
  • [2623]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:147.
  • [2624]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2625]
    (a) a process comprising the steps of:
  • [2626]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2627]
    (aa) SEQ ID NO:147, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:147; and
  • [2628]
    (ab) the nucleotide sequence of the cDNA insert of clone fa1711 deposited under accession number ATCC 207187;
  • [2629]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2630]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2631]
    (b) a process comprising the steps of:
  • [2632]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2633]
    (ba) SEQ ID NO:147, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:147; and
  • [2634]
    (bb) the nucleotide sequence of the cDNA insert of clone fa1711 deposited under accession number ATCC 207187;
  • [2635]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2636]
    (iii) amplifying human DNA sequences; and
  • [2637]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2638]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:147 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:147, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:147. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368.
  • [2639]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2640]
    (a) the amino acid sequence of SEQ ID NO:148;
  • [2641]
    (b) a fragment of the amino acid sequence of SEQ ID NO:148, the fragment comprising eight contiguous amino acids of SEQ ID NO:148; and
  • [2642]
    (c) the amino acid sequence encoded by the cDNA insert of clone fa1711 deposited under accession number ATCC 207187;
  • [2643]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:148. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:148, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:148.
  • [2644]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2645]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149;
  • [2646]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407;
  • [2647]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407;
  • [2648]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone lp5722 deposited under accession number ATCC 207187;
  • [2649]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone lp5722 deposited under accession number ATCC 207187;
  • [2650]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone lp5722 deposited under accession number ATCC 207187;
  • [2651]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone lp5722 deposited under accession number ATCC 207187;
  • [2652]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:150;
  • [2653]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:150;
  • [2654]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2655]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2656]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2657]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:149.
  • [2658]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407; the nucleotide sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407; the nucleotide sequence of the full-length protein coding sequence of clone lp5722 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone lp5722 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone lp5722 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:150, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO:150.
  • [2659]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:149.
  • [2660]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2661]
    (a) a process comprising the steps of:
  • [2662]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2663]
    (aa) SEQ ID NO:149, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:149; and
  • [2664]
    (ab) the nucleotide sequence of the cDNA insert of clone lp5722 deposited under accession number ATCC 207187;
  • [2665]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2666]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2667]
    (b) a process comprising the steps of:
  • [2668]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2669]
    (ba) SEQ ID NO:149, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:149; and
  • [2670]
    (bb) the nucleotide sequence of the cDNA insert of clone lp5722 deposited under accession number ATCC 207187;
  • [2671]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2672]
    (iii) amplifying human DNA sequences; and
  • [2673]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2674]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:149 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:149, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:149. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407.
  • [2675]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2676]
    (a) the amino acid sequence of SEQ ID NO:150;
  • [2677]
    (b) a fragment of the amino acid sequence of SEQ ID NO:150, the fragment comprising eight contiguous amino acids of SEQ ID NO:150; and
  • [2678]
    (c) the amino acid sequence encoded by the cDNA insert of clone lp5722 deposited under accession number ATCC 207187;
  • [2679]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:150. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:150 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:150, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO:150.
  • [2680]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2681]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151;
  • [2682]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035;
  • [2683]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035;
  • [2684]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pe2461 deposited under accession number ATCC 207187;
  • [2685]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pe2461 deposited under accession number ATCC 207187;
  • [2686]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pe2461 deposited under accession number ATCC 207187;
  • [2687]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pe2461 deposited under accession number ATCC 207187;
  • [2688]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:152;
  • [2689]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:152;
  • [2690]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2691]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2692]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2693]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:151.
  • [2694]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035; the nucleotide sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035; the nucleotide sequence of the full-length protein coding sequence of clone pe2461 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone pe2461 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pe2461 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:152, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:152.
  • [2695]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:151.
  • [2696]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2697]
    (a) a process comprising the steps of:
  • [2698]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2699]
    (aa) SEQ ID NO:151, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:151; and
  • [2700]
    (ab) the nucleotide sequence of the cDNA insert of done pe2461 deposited under accession number ATCC 207187;
  • [2701]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2702]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2703]
    (b) a process comprising the steps of:
  • [2704]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2705]
    (ba) SEQ ID NO:151, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:151; and
  • [2706]
    (bb) the nucleotide sequence of the cDNA insert of clone pe2461 deposited under accession number ATCC 207187;
  • [2707]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2708]
    (iii) amplifying human DNA sequences; and
  • [2709]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2710]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:151 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:151, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:151. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035.
  • [2711]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2712]
    (a) the amino acid sequence of SEQ ID NO:152;
  • [2713]
    (b) a fragment of the amino acid sequence of SEQ ID NO:152, the fragment comprising eight contiguous amino acids of SEQ ID NO:152; and
  • [2714]
    (c) the amino acid sequence encoded by the cDNA insert of clone pe2461 deposited under accession number ATCC 207187;
  • [2715]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:152. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:152, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:152.
  • [2716]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2717]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:153;
  • [2718]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281;
  • [2719]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qf1223 deposited under accession number ATCC 207187;
  • [2720]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qf1223 deposited under accession number ATCC 207187;
  • [2721]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qf1223 deposited under accession number ATCC 207187;
  • [2722]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qf1223 deposited under accession number ATCC 207187;
  • [2723]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:154;
  • [2724]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:154;
  • [2725]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2726]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2727]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2728]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:153.
  • [2729]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281; the nucleotide sequence of the full-length protein coding sequence of clone qf1223 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone qf1223 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qf1223 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:154, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:154.
  • [2730]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:153.
  • [2731]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2732]
    (a) a process comprising the steps of:
  • [2733]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2734]
    (aa) SEQ ID NO:153; and
  • [2735]
    (ab) the nucleotide sequence of the cDNA insert of clone qf1223 deposited under accession number ATCC 207187;
  • [2736]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2737]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2738]
    (b) a process comprising the steps of:
  • [2739]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2740]
    (ba) SEQ ID NO:153; and
  • [2741]
    (bb) the nucleotide sequence of the cDNA insert of clone qf1223 deposited under accession number ATCC 207187;
  • [2742]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2743]
    (iii) amplifying human DNA sequences; and
  • [2744]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2745]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:153, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:153 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:153. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281.
  • [2746]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2747]
    (a) the amino acid sequence of SEQ ID NO:154;
  • [2748]
    (b) a fragment of the amino acid sequence of SEQ ID NO:154, the fragment comprising eight contiguous amino acids of SEQ ID NO:154; and
  • [2749]
    (c) the amino acid sequence encoded by the cDNA insert of clone qf1223 deposited under accession number ATCC 207187;
  • [2750]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:154. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:154, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:154.
  • [2751]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2752]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155;
  • [2753]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742;
  • [2754]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742;
  • [2755]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qv5381 deposited under accession number ATCC 207187;
  • [2756]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qv5381 deposited under accession number ATCC 207187;
  • [2757]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qv5381 deposited under accession number ATCC 207187;
  • [2758]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qv5381 deposited under accession number ATCC 207187;
  • [2759]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:156;
  • [2760]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:156;
  • [2761]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2762]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2763]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2764]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:155.
  • [2765]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742; the nucleotide sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742; the nucleotide sequence of the full-length protein coding sequence of clone qv5381 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone qv5381 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qv5381 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:156, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:156.
  • [2766]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:155.
  • [2767]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2768]
    (a) a process comprising the steps of:
  • [2769]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2770]
    (aa) SEQ ID NO:155, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:155; and
  • [2771]
    (ab) the nucleotide sequence of the cDNA insert of clone qv5381 deposited under accession number ATCC 207187;
  • [2772]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2773]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2774]
    (b) a process comprising the steps of:
  • [2775]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2776]
    (ba) SEQ ID NO:155, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:155; and
  • [2777]
    (bb) the nucleotide sequence of the cDNA insert of clone qv5381 deposited under accession number ATCC 207187;
  • [2778]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2779]
    (iii) amplifying human DNA sequences; and
  • [2780]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2781]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:155 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:155, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:155. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742.
  • [2782]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2783]
    (a) the amino acid sequence of SEQ ID NO:156;
  • [2784]
    (b) a fragment of the amino acid sequence of SEQ ID NO:156, the fragment comprising eight contiguous amino acids of SEQ ID NO:156; and
  • [2785]
    (c) the amino acid sequence encoded by the cDNA insert of clone qv5381 deposited under accession number ATCC 207187;
  • [2786]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:156. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:156, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:156.
  • [2787]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2788]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:157;
  • [2789]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757;
  • [2790]
    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ys201 deposited under accession number ATCC 207187;
  • [2791]
    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ys201 deposited under accession number ATCC 207187;
  • [2792]
    (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ys201 deposited under accession number ATCC 207187;
  • [2793]
    (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ys201 deposited under accession number ATCC 207187;
  • [2794]
    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:158;
  • [2795]
    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:158;
  • [2796]
    (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
  • [2797]
    (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above;
  • [2798]
    (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
  • [2799]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:157.
  • [2800]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757; the nucleotide sequence of the full-length protein coding sequence of done ys201 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone ys201 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ys201 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:158, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:158.
  • [2801]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:157.
  • [2802]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2803]
    (a) a process comprising the steps of:
  • [2804]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2805]
    (aa) SEQ ID NO:157, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:157; and
  • [2806]
    (ab) the nucleotide sequence of the cDNA insert of clone ys201 deposited under accession number ATCC 207187;
  • [2807]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2808]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2809]
    (b) a process comprising the steps of:
  • [2810]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2811]
    (ba) SEQ ID NO:157, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:157; and
  • [2812]
    (bb) the nucleotide sequence of the cDNA insert of clone ys201 deposited under accession number ATCC 207187;
  • [2813]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2814]
    (iii) amplifying human DNA sequences; and
  • [2815]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2816]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:157 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:157, but excluding the poly(A) tail at the 3′ end of SEQ ID NO:157. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757.
  • [2817]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2818]
    (a) the amino acid sequence of SEQ ID NO:158;
  • [2819]
    (b) a fragment of the amino acid sequence of SEQ ID NO:158, the fragment comprising eight contiguous amino acids of SEQ ID NO:158; and
  • [2820]
    (c) the amino acid sequence encoded by the cDNA insert of clone ys201 deposited under accession number ATCC 207187;
  • [2821]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:158. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:158, or a protein comprising a fragment of the amino add sequence of SEQ ID NO:158 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:158.
  • [2822]
    In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • [2823]
    (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159;
  • [2824]
    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253;
  • [2825]
    (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253;
  • [2826]
    (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone as1801 deposited under accession number ATCC ______;
  • [2827]
    (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone as1801 deposited under accession number ATCC ______;
  • [2828]
    (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone as1801 deposited under accession number ATCC ______;
  • [2829]
    (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone as1801 deposited under accession number ATCC ______;
  • [2830]
    (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:160;
  • [2831]
    (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:160;
  • [2832]
    (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
  • [2833]
    (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above;
  • [2834]
    (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • [2835]
    (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:159.
  • [2836]
    Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253; the nucleotide sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253; the nucleotide sequence of the full-length protein coding sequence of done as1801 deposited under accession number ATCC ______; or the nucleotide sequence of a mature protein coding sequence of clone as1801 deposited under accession number ATCC ______. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone as1801 deposited under accession number ATCC ______. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:160, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising the amino acid sequence from amino acid 366 to amino acid 375 of SEQ ID NO:160.
  • [2837]
    Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:159.
  • [2838]
    Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • [2839]
    (a) a process comprising the steps of:
  • [2840]
    (i) preparing one or more polynucleotide probes that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2841]
    (aa) SEQ ID NO:159; and
  • [2842]
    (ab) the nucleotide sequence of the cDNA insert of clone as1801 deposited under accession number ATCC ______;
  • [2843]
    (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.; and
  • [2844]
    (iii) isolating the DNA polynucleotides detected with the probe(s); and
  • [2845]
    (b) a process comprising the steps of:
  • [2846]
    (i) preparing one or more polynucleotide primers that hybridize in 6×SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of:
  • [2847]
    (ba) SEQ ID NO:159; and
  • [2848]
    (bb) the nucleotide sequence of the cDNA insert of clone as1801 deposited under accession number ATCC ______;
  • [2849]
    (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4×SSC at 50 degrees C.;
  • [2850]
    (iii) amplifying human DNA sequences; and
  • [2851]
    (iv) isolating the polynucleotide products of step (b)(iii).
  • [2852]
    Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of SEQ ID NO:159 to a nucleotide sequence corresponding to the 3′ end of SEQ ID NO:159. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253, and extending contiguously from a nucleotide sequence corresponding to the 5′ end of said sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253, to a nucleotide sequence corresponding to the 3′ end of said sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253.
  • [2853]
    In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • [2854]
    (a) the amino acid sequence of SEQ ID NO:160;
  • [2855]
    (b) a fragment of the amino acid sequence of SEQ ID NO:160, the fragment comprising eight contiguous amino acids of SEQ ID NO:160; and
  • [2856]
    (c) the amino acid sequence encoded by the cDNA insert of clone as1801 deposited under accession number ATCC ______;
  • [2857]
    the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:160. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:160, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising the amino acid sequence from amino acid 366 to amino acid 375 of SEQ ID NO:160.
  • [2858]
    In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.
  • [2859]
    Processes are also provided for producing a protein, which comprise:
  • [2860]
    (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
  • [2861]
    (b) purifying the protein from the culture.
  • [2862]
    The protein produced according to such methods is also provided by the present invention.
  • [2863]
    Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
  • [2864]
    Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [2865]
    [2865]FIGS. 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.
  • [2866]
    [2866]FIG. 2 is a schematic representation of the pCMVSport2 vector used for deposit of clone qs143 disclosed herein.
  • DETAILED DESCRIPTION
  • [2867]
    Isolated Proteins and Polynucleotides
  • [2868]
    Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
  • [2869]
    As used herein a “secreted” protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. “Secreted” proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. “Secreted” proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
  • [2870]
    Clone “co6212”
  • [2871]
    A polynucleotide of the present invention has been identified as clone “co6212”. co6212 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. co6212 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “co6212 protein”).
  • [2872]
    The nucleotide sequence of co6212 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the co6212 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 1 to 11 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino add sequence beginning at amino acid 12. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the co6212 protein.
  • [2873]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone co6212 should be approximately 2200 bp.
  • [2874]
    The nucleotide sequence disclosed herein for co6212 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. co6212 demonstrated at least some similarity with sequences identified as AA019597 (ze60f10.s1 Soares retina N2b4HR Homo sapiens cDNA), AA021678 (mh82c02.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus), AA057573 (zf62d10.s1 Soares retina N2b4HR Homo sapiens cDNA clone 381523 3′ similar to WP T12G3.4 CE06440 STRICTOSIDINE SYNTHASE LIKE, mRNA sequence), AA130982, AA287697 (zs53g02.r1 Soares NbHTGBC Homo sapiens cDNA clone 701234 5′), AI042188 (oy37d10.x1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE:1668019 3′ similar to WP:F57C2.5 CE16156, mRNA sequence), R63905 (yi19b03.s1 Homo sapiens cDNA clone 139661 3′), T03538 (IB43 Infant brain, Bento Soares Homo sapiens cDNA clone IB43 3′end), T20257 (Human gene signature HUMGS01405), and T23663 (seq294 Homo sapiens cDNA clone b4HB3MA-Cot109+103-Bio-24 3′). The predicted amino acid sequence disclosed herein for co6212 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted co6212 protein demonstrated at least some similarity to sequences identified as R88502 (Protein sequence for mediating male fertility in plants) and Z83110 (F57C2.5 [Caenorhabditis elegans]). Based upon sequence similarity, co6212 proteins and each similar protein or peptide may share at least some activity.
  • [2875]
    Clone “lo3118”
  • [2876]
    A polynucleotide of the present invention has been identified as clone “lo3118”. lo3118 was isolated from a human adult thyroid cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. lo3118 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “lo3118 protein”).
  • [2877]
    The nucleotide sequence of lo3118 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the lo3118 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 17 to 29 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the lo3118 protein.
  • [2878]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone lo3118 should be approximately 3850 bp.
  • [2879]
    The nucleotide sequence disclosed herein for lo3118 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. lo3118 demonstrated at least some similarity with sequences identified as AA046836 (zf14b10.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 376891 5′ similar to WP:ZK686.3 CE00457), AA297716 (EST113273 Infant adrenal gland, subtracted (total cDNA) I Homo sapiens cDNA 5′ end similar to similar to C. elegans hypothetical protein, cosmid ZK6863), AF008554 (Rattus norvegicus implantation-associated protein (IAG2) mRNA, partial cds), T68050 (yc39h10.r1 Homo sapiens cDNA clone 83107 5′ similar to SP ZK686.3 CE00457), and U42349 (Human N33 mRNA, complete cds). The predicted amino acid sequence disclosed herein for lo3118 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted lo3118 protein demonstrated at least some similarity to sequences identified as AF008554 (implantation-associated protein [Rattus norvegicus]), R85333 (Human prostate/colon tumour suppressor protein form 1) and U42349 (39 kDa encoded by N33 [Homo sapiens]). Based upon sequence similarity, lo3118 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the lo3118 protein sequence, centered around amino acids 10, 190, 220, 275, and 310 of SEQ ID NO:4, respectively.
  • [2880]
    Clone “ns1971”
  • [2881]
    A polynucleotide of the present invention has been identified as clone “ns1971”. ns1971 was isolated from a human adult retina (retinoblastoma WERI-Rb1) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ns1971 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ns1971 protein”).
  • [2882]
    The nucleotide sequence of ns1971 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ns1971 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.
  • [2883]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ns1971 should be approximately 3650 bp.
  • [2884]
    The nucleotide sequence disclosed herein for ns1971 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ns1971 demonstrated at least some similarity with sequences identified as AA495135 (fa03c11.r1 Zebrafish ICRFzfls Danio rerio cDNA clone 3K8 5′ similar to WP:ZC518.3 CE06603 ALCOHOL DEHYDROGENASE TRANSCRIPTION EFFECTOR LIKE; mRNA sequence). The predicted amino acid sequence disclosed herein for ns1971 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ns1971 protein demonstrated at least some similarity to the sequence identified as Z68753 (ZC518.3 [Caenorhabditis elegans]). Based upon sequence similarity, ns1971 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ns1971 protein sequence centered around amino acid 135 of SEQ ID NO:6. The nucleotide sequence of ns1971 indicates that it may contain one or more repeat sequences, including primate simple repeat GCC, Alu, and other repetitive elements.
  • [2885]
    Clone “pj11935”
  • [2886]
    A polynucleotide of the present invention has been identified as clone “pj1935”. pj1935 was isolated from a human fetal carcinoma (NTD2 cells, treated with retinoic acid for 23 days) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pj1935 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pj1935 protein”).
  • [2887]
    The nucleotide sequence of pj1935 as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pj1935 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 9 to 21 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino add 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pj1935 protein.
  • [2888]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pj1935 should be approximately 1500 bp.
  • [2889]
    The nucleotide sequence disclosed herein for pj1935 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pj1935 demonstrated at least some similarity with sequences identified as AA296889 (EST112653 Cerebellum II Homo sapiens cDNA 5′ end), AA296961 (EST112514 Adrenal gland tumor Homo sapiens cDNA 5′ end), AA661635 (nv02g06.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1219066), and U80744 (Homo sapiens CTG4a mRNA, complete cds). The predicted amino acid sequence disclosed herein for pj1935 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pj1935 protein demonstrated at least some similarity to the sequence identified as U80744 (CTG4a [Homo sapiens]). Based upon sequence similarity, pj1935 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of pj1935 indicates that it may contain CAG nucleotide repeats; these repeats may create a “hotspot” for certain types of mutations. “Twelve diseases, most with neuropsychiatric features, arise from trinucleotide repeat expansion mutations. Expansion mutations may also cause a number of other disorders, including several additional forms of spinocerebellar ataxia, bipolar affective disorder, schizophrenia, and autism.” (Margolis et al., 1997, Human Genetics 100(1): 114-122, which is incorporated by reference herein.) It is possible that the gene corresponding to pj1935 undergoes a similar etiology.
  • [2890]
    pj1935 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 31 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2891]
    Clone “pj3172”
  • [2892]
    A polynucleotide of the present invention has been identified as clone “pj3172”. pj3172 was isolated from a human fetal carcinoma (NTD2 cells, treated with retinoic acid for 23 days) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pj3172 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pj3172 protein”).
  • [2893]
    The nucleotide sequence of pj3172 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pj3172 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.
  • [2894]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pj3172 should be approximately 2300 bp.
  • [2895]
    The nucleotide sequence disclosed herein for pj3172 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pj3172 demonstrated at least some similarity with sequences identified as AA305508 (EST176494 Colon carcinoma (Caco-2) cell line II Homo sapiens cDNA 5′ end, mRNA sequence), AA471379 (PMY1151 KG1a Lambda Zap Express cDNA Library Homo sapiens cDNA 5′, mRNA sequence), and AA906311 (ok03f08.s1 Soares NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1506759 3′, mRNA sequence). The predicted amino acid sequence disclosed herein for pj3172 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pj3172 protein demonstrated at least some similarity to the sequences identified as U37763 (Per9p [Pichia angusta]) and U56965 (Caenorhabditis elegans cosmid C15H9). Per9p is a peroxisomal membrane protein, and the predicted pj3172 protein demonstrated at least some similarity to peroxisomal proteins from other species as well. Based upon sequence similarity, pj3172 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pj3172 protein sequence centered around amino acid of SEQ ID NO:10. The nucleotide sequence of pj3172 indicates that it may contain a simple AT and MER repeat region.
  • [2896]
    Clone “pt3321”
  • [2897]
    A polynucleotide of the present invention has been identified as clone “pt3321”. pt3321 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pt3321 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pt3321 protein”).
  • [2898]
    The nucleotide sequence of pt3321 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pt3321 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 287 to 299 of SEQ ID NO:12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 300. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pt3321 protein.
  • [2899]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pt3321 should be approximately 3450 bp.
  • [2900]
    The nucleotide sequence disclosed herein for pt3321 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pt3321 demonstrated at least some similarity with sequences identified as AA167221 (zp13c09.s1 Stratagene fetal retina 937202 Homo sapiens cDNA clone 609328 3′), AA437109 (zv53c07.s1 Soares testis NHT Homo sapiens cDNA clone 757356 3′), H14107 (ym62a06.r1 Homo sapiens cDNA clone 163474 5′), and U41264 (C. elegans cDNA). Based upon sequence similarity, pt3321 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pt3321 protein sequence centered around amino acid 270 of SEQ ID NO:12.
  • [2901]
    pt3321 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 100 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2902]
    Clone “qc29715”
  • [2903]
    A polynucleotide of the present invention has been identified as clone “qc29715”. qc29715 was isolated from a human adult neural (neuroepithelioma HTB-10 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qc29715 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qc29715 protein”).
  • [2904]
    The nucleotide sequence of qc29715 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qc29715 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14.
  • [2905]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qc29715 should be approximately 1400 bp.
  • [2906]
    The nucleotide sequence disclosed herein for qc29715 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qc29715 demonstrated at least some similarity with sequences identified as AA625537 (af72g07.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 1047612 5′) and T24537 (EST112 Homo sapiens cDNA clone 4H3). Based upon sequence similarity, qc29715 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the qc29715 protein sequence, around amino acid 20 of SEQ ID NO:14. The nucleotide/amino acid sequence of qc29715 indicates that it may contain an Alu/SVA/MER repeat region.
  • [2907]
    qc29715 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2908]
    Clone “qg59612”
  • [2909]
    A polynucleotide of the present invention has been identified as clone “qg59612”. qg59612 was isolated from a human adult neural (neuroepithelioma HTB-10 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qg59612 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qg59612 protein”).
  • [2910]
    The nucleotide sequence of qg59612 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qg59612 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16.
  • [2911]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qg59612 should be approximately 2750 bp.
  • [2912]
    The nucleotide sequence disclosed herein for qg59612 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qg59612 demonstrated at least some similarity with sequences identified as AA332939 (EST37132 Embryo, 8 week I Homo sapiens cDNA 5′ end), AA334678 (EST39190 Embryo, 9 week Homo sapiens cDNA 5′ end), AA362653 (EST72375 Namalwa B cells I Homo sapiens cDNA 5′ end), and AA829841 (od40d01.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1370401 3′ similar to WP:F10G7.1 CE02624). The predicted amino acid sequence disclosed herein for qg59612 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qg59612 protein demonstrated at least some similarity to the sequence identified as U40029 (coded for by C. elegans cDNA yk16b1.3; coded for by C. elegans cDNA yk8g6.5; coded for by C. elegans cDNA yk8g6.3; coded for by C. elegans cDNA yk6d3.5). Based upon sequence similarity, qg59612 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the qg59612 protein sequence, one centered around amino acid 180 and another around amino acid 660 of SEQ ID NO:16.
  • [2913]
    qg59612 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 33 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2914]
    Clone “rb6493”
  • [2915]
    A polynucleotide of the present invention has been identified as clone “rb6493”. rb6493 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rb6493 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rb6493 protein”).
  • [2916]
    The nucleotide sequence of rb649_as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rb6493 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 42 to 54 of SEQ ID NO:18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 55. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rb6493 protein.
  • [2917]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rb6493 should be approximately 2500 bp.
  • [2918]
    The nucleotide sequence disclosed herein for rb6493 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rb6493 demonstrated at least some similarity with sequences identified as AA177001 (nc01h02.s1 NCI_CGAP_Pr1 Homo sapiens cDNA clone IMAGE 182). The predicted amino acid sequence disclosed herein for rb6493 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rb6493 protein demonstrated at least some similarity to sequences identified as AB002405 (LAK-4p [Homo sapiens]), R89470 (Collagen/TGF-beta-1 fusion protein), and U23516 (Undefined [Caenorhabditis elegans]). Based upon sequence similarity, rb6493 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts eight addditional potential transmembrane domains within the rb6493 protein sequence, centered around amino acids 140, 240, 280, 325, 370, 425, 475, and 540 of SEQ ID NO:18, respectively. The nucleotide sequence of rb6493 indicates that it may contain a simple GGA repeat region.
  • [2919]
    Clone “ca10619x”
  • [2920]
    A polynucleotide of the present invention has been identified as clone “ca10619x”. A cDNA clone was first isolated from a mouse embryonic (ES cell embryoid bodies harvested 2-12 days after LIF removed) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate ca10619x from a mixture of human fetal brain and human adult brain cDNA libraries.
  • [2921]
    ca10619x is a full-length human clone, including the entire coding sequence of a secreted protein (also referred to herein as “ca10619x protein”).
  • [2922]
    The nucleotide sequence of ca10619x as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ca10619x protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20.
  • [2923]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ca10619x should be approximately 4050 bp.
  • [2924]
    The nucleotide sequence disclosed herein for ca10619x was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ca10619x demonstrated at least some similarity with sequences identified as AA886998 (oj30g03.s1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1499860 3′), F08279 (H. sapiens partial cDNA sequence; clone c-zpe11), F13022 (H. sapiens partial cDNA sequence; clone c-3hf07), H38128 (yp46c12.s1 Homo sapiens cDNA done 190486 3′), T77601 (yc91e07.r1 Homo sapiens cDNA done 23192 5′), U93720 (Homo sapiens TEX28 mRNA, complete cds), W55512 (ma28h03.r1 Life Tech mouse brain Mus musculus cDNA clone 312053 5′), and Z22333 (H.sapiens DNA sequence). The predicted amino acid sequence disclosed herein for ca10619x was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ca10619x protein demonstrated at least some similarity to sequences identified as U56965 (C15H9.4 gene product [Caenorhabditis elegans]) and U93720 (TEX28 [Homo sapiens]). Based upon sequence similarity, ca10619x proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the ca10619x protein sequence, centered around amino acids 170, 430, 590, and 625 of SEQ ID NO:20, respectively. The nucleotide sequence of ca10619x indicates that it contains at least one repetitive element.
  • [2925]
    Clone “ci522”
  • [2926]
    A polynucleotide of the present invention has been identified as clone “ci522”. A cDNA clone was first isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate ci522 from a human fetal brain cDNA library. ci522 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “ci522 protein”).
  • [2927]
    The nucleotide sequence of ci522 as presently determined is reported in SEQ ID NO:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ci522 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:22. Amino acids 9 to 21 of SEQ ID NO:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ci522 protein.
  • [2928]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ci522 should be approximately 1775 bp.
  • [2929]
    The nucleotide sequence disclosed herein for ci522 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ci522 demonstrated at least some similarity with sequences identified as AA083339 (zn31d10.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 549043 5′), AA514339 (nf56c10.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 923922), AA628942 (af28f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032985 3′, mRNA sequence), M78692 (EST00840 Homo sapiens cDNA clone HHCMC16), N67265 (yz49d04.s1 Homo sapiens cDNA clone 286375 3′), N95514 (yy62d10.r1 Homo sapiens cDNA clone 278131 5′), Q60715 (Human brain Expressed Sequence Tag EST00840; standard; cDNA), and R46588 (yg51a12.s1 Homo sapiens cDNA clone 35984 3′). The predicted amino acid sequence disclosed herein for ci522 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ci522 protein demonstrated at least some similarity to the sequence identified as M68866 (stranded at second [Drosophila melanogaster]). Based upon sequence similarity, ci522 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the ci522 protein sequence, one around amino acid 146 and another around amino acid 177 of SEQ ID NO:22.
  • [2930]
    Clone “md12416”
  • [2931]
    A polynucleotide of the present invention has been identified as clone “md12416”. A cDNA clone was first isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate md12416 from a human adult kidney cDNA library. md12416 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “md12416 protein”).
  • [2932]
    The nucleotide sequence of md12416 as presently determined is reported in SEQ ID NO:23, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the md12416 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 152 to 164 of SEQ ID NO:24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 165. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the md12416 protein.
  • [2933]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone md12416 should be approximately 2300 bp.
  • [2934]
    The nucleotide sequence disclosed herein for md12416 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. md12416 demonstrated at least some similarity with sequences identified as AA215643 (zr98d05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone MAGE:683721 3′), AA489121 (aa56b07.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824917 5′), W72865 (zd59e07.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344964 3′), and W76100 (zd59e07.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344964 5′). Based upon sequence similarity, md12416 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of md12416 indicates that it may contain at least one MER repeat sequence.
  • [2935]
    Clone “pk3667”
  • [2936]
    A polynucleotide of the present invention has been identified as clone “pk3667”. pk3667 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pk3667 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pk3667 protein”).
  • [2937]
    The nucleotide sequence of pk3667 as presently determined is reported in SEQ ID NO:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pk3667 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:26. Amino acids 361 to 373 of SEQ ID NO:26 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 374. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pk3667 protein.
  • [2938]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pk3667 should be approximately 3300 bp.
  • [2939]
    The nucleotide sequence disclosed herein for pk3667 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pk3667 demonstrated at least some similarity with sequences identified as AA057428 (zf57c11.s1 Soares retina N2b4HR Homo sapiens cDNA clone 381044 3′), AA457625 (aa89e09.r1 Stratagene fetal retina 937202 Homo sapiens cDNA clone 838504 5′), AA601545 (nn87h11.s1 NCI_CGAP_Br2 Homo sapiens cDNA clone IMAGE:1098213), T19564 (Human gene signature HUMGS00629; standard; cDNA to mRNA), and U94831 (Homo sapiens multispanning membrane protein mRNA, complete cds). The predicted amino acid sequence disdosed herein for pk3667 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pk3667 protein demonstrated at least some similarity to sequences identified as D87444 (endomembrane protein EMP70 precursor isolog [Arabidopsis thaliana]), U94831 (multispanning membrane protein [Homo sapiens]), and U95973 (endomembrane protein EMP70 precusor isolog [Arabidopsis thaliana]). Based upon sequence similarity, pk3667 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts nine additional potential transmembrane domains within the pk3667 protein sequence, centered around amino adds 191, 260, 288, 325, 355, 412, 447, 481, and 517 of SEQ ID NO:26, respectively.
  • [2940]
    Clone “pl741 5”
  • [2941]
    A polynucleotide of the present invention has been identified as clone “pl7415”. pl7415 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pl7415 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pl7415 protein”).
  • [2942]
    The nucleotide sequence of pl7415 as presently determined is reported in SEQ ID NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pl7415 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28. Amino acids 3 to 15 of SEQ ID NO:28 are a predicted leader/signal sequence, with the predicted mature amino add sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pl7415 protein.
  • [2943]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pl7415 should be approximately 3000 bp.
  • [2944]
    The nucleotide sequence disclosed herein for pl7415 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pl7415 demonstrated at least some similarity with sequences identified as AA283176 (zt17a04.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 713358 3′), AA204801 (zq61d12.r1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 646103 5′), and H59410 (yr19g04.r1 Homo sapiens cDNA clone 205782 5′). The predicted amino acid sequence disclosed herein for pl7415 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pl741-5 protein demonstrated at least some similarity to sequences identified as U00027 (Cdc23p cell cycle protein [Saccharomyces cerevisiae]) and U58763 (F10C5.1 [Caenorhabditis elegans]). Based upon sequence similarity, pl741-5 proteins and each similar protein or peptide may share at least some activity. Analysis of the amino acid sequence of the predicted pl741-5 protein reveals the presence of four TPR (tetratricopeptide) domains. TPR domains are found in a wide variety of proteins with varying functions and localizations—from the nucleus to the extracellular milieu—and are thought to function as protein-protein interaction domains. The TPR domains are found at amino acid residues 166-194, 328-356, 362-390, and 396-424 of SEQ ID NO:28.
  • [2945]
    Clone “pp31419”
  • [2946]
    A polynucleotide of the present invention has been identified as clone “pp31419”. pp31419 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pp31419 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pp31419 protein”).
  • [2947]
    The nucleotide sequence of pp31419 as presently determined is reported in SEQ ID NO:29, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pp31419 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 147 to 159 of SEQ ID NO:30 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 160; amino acids 238 to 250 of SEQ ID NO:30 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 251. Due to the hydrophobic nature of these possible leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the pp31419 protein.
  • [2948]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pp31419 should be approximately 2300 bp.
  • [2949]
    The nucleotide sequence disclosed herein for pp31419 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pp31419 demonstrated at least some similarity with sequences identified as AA044042 (zk58g05.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487064 5′, mRNA sequence), AA127902 (zl12d01.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 501697 5′), AA609481 (af14a12.s1 Soares testis NHT Homo sapiens cDNA clone 1031614 3′, mRNA sequence), T26699 (Human gene signature HUMGS08949; standard; cDNA to mRNA), and W93399 (zd95b06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 357203 3′). The predicted amino acid sequence disclosed herein for pp31419 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pp31419 protein demonstrated at least some similarity to sequences identified as AE000857 (chaperonin [Methanobacterium thermoautotrophicum]), AJ006549 (ThsA [Pyrodictium occultum]), and L34691 (thermophilic factor 56 [Sulfolobus shibatae]). Based upon sequence similarity, pp31419 proteins and each similar protein or peptide may share at least some activity. Analysis of the amino acid sequence of the predicted pp31419 protein revealed the cpn60_TCP1 signature (at amino acids 29-570 of SEQ ID NO:30) which has some ATPase activity and is indicative of chaperonins. A P-loop motif—a common motif in ATP- and GTP-binding proteins—is found around amino acid 200 of SEQ ID NO:30. The presence of the P-loop is interesting when taken in conjunction with the potential ATPase activity associated with the cpn60_TCP1 signature. The TopPredII computer program predicts three additional potential transmembrane domains within the pp31419 protein sequence, centered around amino acids 55, 90, and 330 of SEQ ID NO:30, respectively.
  • [2950]
    pp31419 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 6 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2951]
    Clone “pv351”
  • [2952]
    A polynucleotide of the present invention has been identified as clone “pv351”. pv351 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pv351 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pv351 protein”).
  • [2953]
    The nucleotide sequence of pv351 as presently determined is reported in SEQ ID NO:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pv351 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:32.
  • [2954]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing done pv351 should be approximately 2300 bp.
  • [2955]
    The nucleotide sequence disclosed herein for pv351 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pv351 demonstrated at least some similarity with sequences identified as AA335869 (EST40348 Epididymus Homo sapiens cDNA 5′ end), AA599418 (ag23c03.s1 Jia bone marrow stroma Homo sapiens cDNA clone 1071172 3′), and H03595 (yj42e06.r1 Homo sapiens cDNA clone 151426 5′). The predicted amino acid sequence disclosed herein for pv351 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pv351 protein demonstrated at least some similarity to sequences identified as Z99277 (Y53C12A.3 [Caenorhabditis elegans]). Based upon sequence similarity, pv351 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the pv351 protein sequence, centered around amino acids 127, 161, 192, and 250 of SEQ ID NO:32, respectively.
  • [2956]
    Clone “pw3376”
  • [2957]
    A polynucleotide of the present invention has been identified as clone “pw3376”. pw3376 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pw3376 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pw3376 protein”).
  • [2958]
    The nucleotide sequence of pw3376 as presently determined is reported in SEQ ID NO:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pw3376 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:34. Another potential pw3376 reading frame and predicted amino acid sequence is encoded by basepairs 648 to 908 of SEQ ID NO:33 and is reported in SEQ ID NO:238. The overlapping reading frames of SEQ ID NO:34 and SEQ ID NO:238 could be joined if a frameshift were introduced into the nucleotide sequence of SEQ ID NO:33 between position 645 and position 736.
  • [2959]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pw3376 should be approximately 1000 bp.
  • [2960]
    The nucleotide sequence disclosed herein for pw3376 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pw3376 demonstrated at least some similarity with sequences identified as AA682471 (zj18c02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 450626 3′, mRNA sequence), T20708 (Human gene signature HUMGS01925; standard; cDNA to mRNA), W24658 (zb63b05.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 308241 5′), and Z82192 (Homo sapiens DNA sequence from PAC 186O1 on chromosome 22). The predicted amino acid sequence disclosed herein for pw3376 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pw3376 protein demonstrated at least some similarity to the sequence identified as Z82192 (dJ186O1.1 [Homo sapiens]). Based upon sequence similarity, pw3376 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pw3376 protein sequence centered around amino acid 75 of SEQ ID NO:34. The nucleotide sequence of pw3376 indicates that it may contain one or more repetitive elements.
  • [2961]
    pw3376 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 22 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2962]
    Clone “rd6101”
  • [2963]
    A polynucleotide of the present invention has been identified as clone “rd6101”. rd6101 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd6101 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rd6101 protein”).
  • [2964]
    The nucleotide sequence of rd6101 as presently determined is reported in SEQ ID NO:35, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd6101 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:36.
  • [2965]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd6101 should be approximately 1800 bp.
  • [2966]
    The nucleotide sequence disclosed herein for rd6101 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd6101 demonstrated at least some similarity with sequences identified as AA442056 (zw56f08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 774087 5′), AA992905 (ot92b06.s1 Soares_total_fetus_Nb2HF89w Homo sapiens cDNA clone IMAGE 1624211 3′, mRNA sequence), D31767 (Human mRNA for KIAA0058 gene, complete cds), and T40090 (Human Serrate-1 (HJ1) cDNA; standard; cDNA). Based upon sequence similarity, rd6101 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rd6101 protein sequence centered around amino acid of SEQ ID NO:36; amino acids 23 to 35 of SEQ ID NO:36 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 36.
  • [2967]
    rd6101 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.
  • [2968]
    Clone “rd8106”
  • [2969]
    A polynucleotide of the present invention has been identified as clone “rd8106”. rd8106 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd8106 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “rd8106 protein”).
  • [2970]
    The nucleotide sequence of rd8106 as presently determined is reported in SEQ ID NO:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd8106 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:38. Amino acids 112 to 124 of SEQ ID NO:38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 125. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rd8106 protein.
  • [2971]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd8106 should be approximately 850 bp.
  • [2972]
    The nucleotide sequence disclosed herein for rd8106 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd8106 demonstrated at least some similarity with sequences identified as AA452718 (zx39d04.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 788839 5′, mRNA sequence), AA292888 (zt66c01.r1 Soares testis NHT Homo sapiens cDNA clone 727296 5′), and T23348 (Human gene signature HUMGS05169; standard; cDNA to mRNA). Based upon sequence similarity, rd8106 proteins and each similar protein or peptide may share at least some activity.
  • [2973]
    rd8106 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 23 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2974]
    Clone “cf851”
  • [2975]
    A polynucleotide of the present invention has been identified as clone “cf851”. A cDNA clone was first isolated from a human adult placenta library cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate cf851 from a human adult brain cDNA library. cf851 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “cf851 protein”).
  • [2976]
    The nucleotide sequence of cf851 as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cf851 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:40.
  • [2977]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cf851 should be approximately 2000 bp.
  • [2978]
    The nucleotide sequence disclosed herein for cf851 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and PASTA search protocols. cf851 demonstrated at least some similarity with sequences identified as H50932 (yo35f03.r1 Homo sapiens cDNA clone 179933 5′), H51595 (yo35f03.s1 Homo sapiens cDNA clone 179933 3′), and T24664 (Human gene signature HUMGS06728; standard; cDNA to mRNA). Based upon sequence similarity, cf851 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the cf851 protein sequence, centered around amino acids 150, 195, and 220 of SEQ ID NO:40, respectively. The nucleotide sequence of cf851 indicates that it may contain an Alu repetitive element.
  • [2979]
    Clone “dd50418”
  • [2980]
    A polynucleotide of the present invention has been identified as clone “dd50418”. dd50418 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dd50418 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “dd50418 protein”).
  • [2981]
    The nucleotide sequence of dd50418 as presently determined is reported in SEQ ID NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dd50418 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 134 to 146 of SEQ ID NO:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 147. Amino acids 7 to 19 of SEQ ID NO:42 are also a possible leader/signal sequence, with a predicted mature amino acid sequence beginning in that case at amino acid 20. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the dd50418 protein.
  • [2982]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dd50418 should be approximately 2000 bp.
  • [2983]
    The nucleotide sequence disclosed herein for dd50418 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dd50418 demonstrated at least some similarity with sequences identified as AA393779 (zt77f07.r1 Soares testis NHT Homo sapiens cDNA clone 728389 5′ similar to WP:F41E7.1 CE03301; mRNA sequence), AA429420 (zw51f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773595 5′ similar to WP W02B12.7 CE03767 KINENSIN-LIKE PROTEIN), AC002038 (*** SEQUENCING IN PROGRESS *** Human chromosome 16p12 BAC clone CIT987SK-101B6; HTGS phase 1, 1 unordered pieces; Homo sapiens chromosome 2 clone 101B6 from 2p11, complete sequence), H10672 (yl99g09.r1 Homo sapiens cDNA clone 46448 5′), and R59895 (yh07f12.r1 Homo sapiens cDNA clone 42477 5′). The predicted amino acid sequence disclosed herein for dd50418 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted dd50418 protein demonstrated at least some similarity to sequences identified as AE000854 (Na+/H+-exchanging protein Na+/H+antiporter [Methanobacterium thermoautotrophicum]) and Z68106 (F41E7.1 [Caenorhabditis elegans]). Based upon sequence similarity, dd50418 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts eight potential transmembrane domains within the dd50418 protein sequence, centered around amino acids 20, 48, 118, 144, 191, 220, 268, and 326 of SEQ ID NO:42, respectively.
  • [2984]
    dd50418 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 36 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2985]
    Clone “np263”
  • [2986]
    A polynucleotide of the present invention has been identified as clone “np263”. np263 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. np263 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “np263 protein”).
  • [2987]
    The nucleotide sequence of np263 as presently determined is reported in SEQ ID NO:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the np263 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:44.
  • [2988]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone np263 should be approximately 3800 bp.
  • [2989]
    The nucleotide sequence disclosed herein for np263 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. np263 demonstrated at least some similarity with sequences identified as AA118527 (mo99d08.r1 Stratagene mouse heart (#937316) Mus musculus cDNA clone 567855 5′), AA284633 (zt15d04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:713191 3′, mRNA sequence), AA427620 (zw30d02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 770787 3′ similar to contains MER17.b1 MER17 repetitive element; mRNA sequence), and AA496955 (aa42f01.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 823609 3′, mRNA sequence). The predicted amino acid sequence disclosed herein for np263 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted np263 protein demonstrated at least some similarity to the sequence identified as M86752 (transformation-sensitive protein [Homo sapiens]). Based upon sequence similarity, np263 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the np263 protein sequence centered around amino acid 146 of SEQ ID NO:44.
  • [2990]
    np263 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 63 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.
  • [2991]
    Clone “pm41212”
  • [2992]
    A polynucleotide of the present invention has been identified as clone “pm41212”. pm41212 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pm41212 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pm41212 protein”).
  • [2993]
    The nucleotide sequence of pm41212 as presently determined is reported in SEQ ID NO:45, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pm41212 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:46. Amino acids 607 to 619 of SEQ ID NO:46 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 620. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the pm41212 protein.
  • [2994]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm41212 should be approximately 4000 bp.
  • [2995]
    The nucleotide sequence disclosed herein for pm41212 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm41212 demonstrated at least some similarity with sequences identified as AA176820 (zp34a12.s1 Stratagene muscle 937209 Homo sapiens cDNA clone 611326 3′), AA425762 (zw47f10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773227 3′ similar to TR:G285999 G285999 ORF, COMPLETE CDS), AA568580 (nm21a10.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1060794 similar to TR:G642306 G642306 HYPOTHETICAL 153.8 KD PROTEIN), AA610863 (np98h01.s1 NCI_CGAP_Lu1 Homo sapiens cDNA clone IMAGE 1142449 similar to TR G285999 G285999 ORF, COMPLETE CDS), AA769312 (nz39f06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1290179 similar to TR Q15393 Q15393 ORF, COMPLETE CDS; mRNA sequence), D13642 (Human mRNA for KIAA0017 gene, complete cds), and T92977 (ye22e09.r1 Homo sapiens cDNA clone 118504 5′). The predicted amino acid sequence disclosed herein for pm41212 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pm41212 protein demonstrated at least some similarity to sequences identified as AF043699 (ORF; similar to human UV-damaged DNA binding factor [C. elegans]), D13642 (KIAA0017 [Homo sapiens]), R72386 (XAP-1, part of the DNA repair complex), and X54413 (alpha1(IX) collagen precursor [Homo sapiens]). Based upon sequence similarity, pm41212 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the pm41212 protein sequence, centered around amino acids 277, 415, and 1060 of SEQ ID NO46, respectively.
  • [2996]
    pm41212 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 119 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [2997]
    Clone “pm4213”
  • [2998]
    A polynucleotide of the present invention has been identified as done “pm4213”. pm4213 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pm4213 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pm4213 protein”).
  • [2999]
    The nucleotide sequence of pm4213 as presently determined is reported in SEQ ID NO:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pm4213 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Amino acids 10 to 22 of SEQ ID NO:48 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pm4213 protein.
  • [3000]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm4213 should be approximately 2800 bp.
  • [3001]
    The nucleotide sequence disclosed herein for pm4213 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm4213 demonstrated at least some similarity with sequences identified as AA196485 (zq59a06.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 645874 3′), AA421712 (zu26g11.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 739172 5′, mRNA sequence), AC005026 (Homo sapiens clone GS489L14; HTGS phase 1, 3 unordered pieces), AC005028 (Homo sapiens clone GS539F22; HTGS phase 1, 1 unordered pieces), Q60534 (Human brain Expressed Sequence Tag EST02540; standard; cDNA), and R13985 (yf68h04.r1 Homo sapiens cDNA clone 27722 5′). Based upon sequence similarity, pm4213 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the pm4213 protein sequence centered around amino acid 36 of SEQ ID NO:48.
  • [3002]
    Clone “pv61”
  • [3003]
    A polynucleotide of the present invention has been identified as clone “pv61”. pv61 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pv61 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “pv61 protein”).
  • [3004]
    The nucleotide sequence of pv61 as presently determined is reported in SEQ ID NO:49, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pv61 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:50. Amino acids 39 to 51 of SEQ ID NO:50 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 52. Amino acids 8 to 20 of SEQ ID NO:50 are also a possible leader/signal sequence, with a predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the pv61 protein.
  • [3005]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pv61 should be approximately 1800 bp.
  • [3006]
    The nucleotide sequence disclosed herein for pv61 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pv61 demonstrated at least some similarity with sequences identified as B53192 (CIT-HSP-2009D9.TR CIT-HSP Homo sapiens genomic clone 2009D9, genomic survey sequence), R18429 (yg02g05.r1 Homo sapiens cDNA clone 31056 5′), T77089 (yc93b02.r1 Homo sapiens cDNA clone 23653 5′), and X89480 (S.scrofa mRNA for membrane protein). The predicted amino acid sequence disclosed herein for pv61 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pv61 protein demonstrated at least some similarity to the sequence identified as X89480 (transmembrane protein [Sus scrofa]). Based upon sequence similarity, pv61 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pv61 protein sequence centered around amino acid 21 of SEQ ID NO:50.
  • [3007]
    Clone “qs143”
  • [3008]
    A polynucleotide of the present invention has been identified as clone “qs143”. A cDNA clone was isolated from a human whole embryo cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate qs143 from a human fetal heart cDNA library. qs143 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qs143 protein”).
  • [3009]
    The nucleotide sequence of qs143 as presently determined is reported in SEQ ID NO:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qs143 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:52. Amino acids 15 to 27 of SEQ ID NO:52 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qs143 protein.
  • [3010]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qs143 should be approximately 5000 bp.
  • [3011]
    The nucleotide sequence disclosed herein for qs143 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qs143 demonstrated at least some similarity with sequences identified as AA558554 (nl69g02.s1 NCI_CGAP_Pr4.1 Homo sapiens cDNA clone IMAGE 1045970 similar to TR G307329 G307329 PROTOCADHERIN 43), AB002343 (Human mRNA for KIAA0345 gene), and L43592 (Rattus norvegicus protocadherin-3 (pcdh3) mRNA, and translated products). The predicted amino acid sequence disclosed herein for qs143 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASIX search protocol. The predicted qs143 protein demonstrated at least some similarity to sequences identified as AF029343 (protocadherin [Homo sapiens]), AF042192 (protocadherin [Xenopus]), AF052685 (protocadherin 43 [Homo sapiens]), L11373 (protocadherin 43 [Homo sapiens]), R49144 (Product of alternative splicing of human protocadherin-43 mRNA), and Y08715 (protocadherin [Mus musculus]). The cadherins are a family of calcium-binding membrane glycoproteins. Most cadherins are capable of acting as cell adhesion molecules (CAMs). Motif analysis of the predicted qs143 protein also detects the ‘cadherins extracellular repeated domain signature’. Based upon sequence similarity, qs143 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the qs143 protein sequence, one centered around amino acid 510 and another around amino acid 721 of SEQ ID NO:52.
  • [3012]
    qs143 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 132 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.
  • [3013]
    Clone “qy3389”
  • [3014]
    A polynucleotide of the present invention has been identified as clone “qy3389”. qy3389 was isolated from a human adult blood (promyelocytic leukemia HL-60) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qy3389 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as “qy3389 protein”).
  • [3015]
    The nucleotide sequence of qy3389 as presently determined is reported in SEQ ID NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qy3389 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:54. Amino acids 144 to 156 of SEQ ID NO:54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 157. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qy3389 protein.
  • [3016]
    The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qy3389 should be approximately 1300 bp.
  • [3017]
    The nucleotide sequence disclosed herein for qy3389 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qy3389 demonstrated at least some similarity with sequences identified as AA205412 (zq66a09.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 646552 3′ similar to contains Alu repetitive element; contains element LTR1 repetitive element; mRNA), AA595068 (no40h10.s1 NCI_CGAP_Pr23 Homo sapiens cDNA clone IMAGE 1103203 similar to WP C27F2.4 CE01171 METHYLTRANSFERASE), AJ224442 (Homo sapiens mRNA for putative methyltransferase), and H40834 (yo05g09.r1 Homo sapiens cDNA clone 177088 5′). The predicted amino acid sequence disclosed herein for qy3389 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qy3389 protein demonstrated at least some similarity to sequences identified as AJ224442 (methyl-transferase [Homo sapiens]), U40419 (similar to S. cerevisiae gene YCR47C, putative 30.7 kd methyltransferase (SP YCT7_YEAST, P25627) [Caenorhabditis elegans]), and Z69240 (putative methyltransferase [S. cerevisiae]). Based upon sequence similarity, qy3389 proteins and each similar protein or peptide may share at least some activity.
  • [3018]
    qy3389 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 34 kDa wa